Natural and Synthetic Lactones Possessing Antitumor Activities by 심태보
 International Journal of 
Molecular Sciences
Review
Natural and Synthetic Lactones Possessing Antitumor Activities
Younghoon Kim 1,2 , Sandip Sengupta 2 and Taebo Sim 1,2,*


Citation: Kim, Y.; Sengupta, S.; Sim,
T. Natural and Synthetic Lactones
Possessing Antitumor Activities. Int.




Received: 30 November 2020
Accepted: 16 January 2021
Published: 21 January 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro,
Seongbuk-gu, Seoul 02841, Korea; YHOON9408@yuhs.ac
2 Severance Biomedical Science Institute, Graduate School of Medical Science (Brain Korea 21 Project),
College of Medicine, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea;
SENGSANDIP@yuhs.ac
* Correspondence: TBSIM@yuhs.ac; Tel.: +82-2-2228-0797
Abstract: Cancer is one of the leading causes of death globally, accounting for an estimated 8 million
deaths each year. As a result, there have been urgent unmet medical needs to discover novel oncology
drugs. Natural and synthetic lactones have a broad spectrum of biological uses including anti-
tumor, anti-helminthic, anti-microbial, and anti-inflammatory activities. Particularly, several natural
and synthetic lactones have emerged as anti-cancer agents over the past decades. In this review,
we address natural and synthetic lactones focusing on their anti-tumor activities and synthetic routes.
Moreover, we aim to highlight our journey towards chemical modification and biological evaluation
of a resorcylic acid lactone, L-783277 (4). We anticipate that utilization of the natural and synthetic
lactones as novel scaffolds would benefit the process of oncology drug discovery campaigns based
on natural products.
Keywords: natural lactones; synthetic lactones; anticancer activities; natural product synthesis;
drug discovery
1. Introduction
Cancer, the second leading cause of death worldwide, has become one of the greatest
challenges to global health. The mortality rate that results from cancer is still unacceptably
high over the last two decades, responsible for about 8 million deaths per year, and it is
predicted to increase to 13 million by 2030 [1,2]. Hence, there is a consistent and urgent
need for the discovery of novel and potential chemotherapeutic agents to combat cancer.
Cancer is frequently correlated with disruption in key signaling pathways, which
involve extracellular ligands, transmembrane receptors, intracellular signaling protein ki-
nases, and transcription factors, causing aberrant cell proliferation and defective apoptosis
induction [3,4]. Recently, the targets and molecular mechanisms of natural product-derived
anticancer agents have been extensively investigated [5,6]. Furthermore, the effort has even-
tually led to the emergence of various natural lactones and their derivatives as potential
lead compounds for anticancer therapeutics on account of their potent bioactivities, includ-
ing cytotoxicity against cancer cells and anti-neoplastic efficacy in in vivo studies [7–9].
Lactones are basically chemical entities constituted of cyclic carboxylic esters. Nat-
ural and synthetic lactones exhibit a broad spectrum of biological activities such as anti-
helminthic, anti-microbial, anti-inflammatory, and anti-tumor activities. Radicicol (1),
for instance, is a macrocyclic resorcylic acid lactone and its first isolation dates back to
1953 [10]. Initial biological activity of resorcylic acid lactones, however, did not draw much
attention from the researchers until kinase inhibition by cis-enone-containing resorcylic
acid lactones is reported in the late 1990s [11].
Starting from a series of resorcylic acid lactones (RALs), several classes of natural
lactones including sesquiterpene lactones (SLs), diacylglycerol lactones (DAGLs), and diter-
pene lactones (DLs) received much attention as potential anticancer agents over the past
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few decades [12–16]. Nevertheless, the development of those natural products into drug
discovery programs is still somewhat limited due to complexity in structures and low phar-
macokinetic profile resulted from relatively high lipophilic properties. For this reason, great
efforts were made to complete total syntheses of biologically important natural lactones
and to establish synthetic approaches to modify complex natural lactone structures [17–19].
In the expectation that natural products-based structures would be amply exploited as
powerful tools in designing strategies of anticancer drug discovery programs, we herein
provide a comprehensive review on the biological activities and chemistry of representative
natural and synthetic lactones that are known to exhibit anticancer activities.
2. Biological Activities and Chemistry of Natural and Synthetic Lactones
2.1. Reosorcylic Acid Lactones
The resorcylic acid lactones (RALs) are mucotoxins belonging to a family of benzan-
nulated macrolides, which are isolated from various types of fungi. A structural feature
of RALs is characterized by a β-resorcylic acid scaffold annulated to a 12–14 membered
macrolactone [20]. RALs had not been recognized as a significant class of compounds
until the late 1990s that molecular targets of a few RALs were revealed. Research on RALs
was delighted with the discovery of radicicol (1) as an Hsp90 inhibitor in conjunction
with the identification of hypothemycin (2) and L783277 (3) as kinase inhibitors [11,21,22].
Especially, cis-enone moiety containing RALs are prone to undergo 1,4-Michael addition
with a conserved cysteine residue in the ATP-binding site of the kinases leading to co-
valent inhibition of the target kinase. The most recognized compounds of this type are
hypothemycin (2), LL-Z1604-2 (3), and L783277 (4).
2.1.1. Biological Activities of Radicicol (1)
Radicicol (1) provided the foundation for research on macrocylic lactones as anticancer
agents. In 1953, Radicicol (1) was isolated from the fungus Monosporium bonorden as the
first example of RALs [10]. In 1992, radicicol (1) was initially reported to act as an src
kinase inhibitor, which triggered research interest in RALs and other classes of macrocyclic
lactones [23]. However, radicicol (1) was later revealed to selectively inhibit HSP90 function
by binding to its N-terminal ATP pocket and the effects of radicicol (1) on modulating
protein kinase activity turned out to be indirect as many protein kinases require HSP90
for proper folding [24]. Although radicicol (1) does not possess direct kinase inhibitory
activity, it provided the foundation for research on macrocylic lactones as anticancer agents.
Owing to radicicol (1), there are currently several examples of well-studied RALs, namely:
hypothemycin (2), LL-Z1640-2 (3), and L-783277 (4) that are known to inhibit mitogen-
activated protein kinases by the use of a cis-enone moiety in an ATP-competitive manner
(Figure 1).
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2.1.2. Chemistry of Radicicol (1)
Affirmation of the structure was achieved by the total synthesis accomplished by
Lett and Lampilas in early 1992 and followed by some improvement and modification.
Lett’s synthetic protocol utilized a key intramolecular Mitsunobu reaction to construct
the 14-member macrocycle (Scheme 1). Cyclization precursor 9 would be synthesized
through a palladium-catalyzed coupling reaction of chlorinated isocoumarin 8 and vinyltin
substrate 7. Compound 7 was obtained through the addition of lithium vinyltin 6 to
aldehyde 5 already carrying the epoxide with the desired stereochemistry in place. involved
18 linear steps resulting in a 4.7% overall yield [25].
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In 2000, the Danishefsky group did concise asymmetric syntheses of radicicol (1) and
monocillin I [26]. Their synthetic strategy relies on a convergent three-stage assembly of the
14-membered lactone which has, as a key transformation, a novel ring-forming metathesis
reaction utilizing a vinyl epoxide (Figure 2).
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The synthesis commenced with construction of the chiral homochiral allylic alcohol
11 from methyl (R)-3-hydroxybutyric acid (13) in 8 steps in 49% yield (Scheme 2).
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The allylic dithiane 12 was prepared in one step from commercially available 2,4-
hexadienal 14 with 64% yield (Scheme 3).
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Scheme 3. Synthesis of intermediate 12 [26].
Formylation followed by oxidation and conversion of the alcohol to chloride was
effected with 3,5-dimethoxybenzyl alcohol 14 to give the desired acid 15 (Scheme 4).
Intermediate 16 was synthesized in 2 steps from 15 with 48% yield. Ruthenium-based olefin
metathesis catalyst was used to get the desired 14-membered lactone 18 stereospecifically
in 55% yield. Oxidation and crude monosulfoxide was exposed to the action of Ac2O,
Et3N, and H2O to give the desired ketone dimethyl monocillin I (19, 70%). Regiospecific
chlorination of the aromatic ring then produced radicicol dimethyl ether (20).
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However, they were able to reform the natural products via the similar strategy used
before except the modification of protectio groups in the aromatic ring 21 (Scheme 5).
They obtained the final rad cicol (1) by treatment with base, in 7.5% yield over 14 steps
(longest linear seque ce) [27].
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Winssinger’s total synthesis of radicicol (1) was reported in 2005 [28]. 2-hydroxy toluic
acid 22 under Mitsunobu condition with 23 and protection gave 24 (Scheme 6). Reaction
of toluate 24 using two equivalents of LDA followed by addition of Weinreb amide 25
afforded cyclization precursor, which after elimination and Grubbs reaction produced 26
with 64% yield in 3 steps. Radicicol (1) was obtained from intermediate 26 in 3 steps with
43% yield.
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The central element of their plan was the building of an “ynolide” intermediate and
its advancement to the benzomacrolide by a Diels–Alder cycloaddition. Reformatsky-like
condensation of propargyl bromide 27 with 28, followed by protection and subsequent
reaction of the lithium alkynide ion, gave them the acid intermediate 29, which under
Mitsonobu condition, furnished ester 30. Cyclopropane-containing cobalt complex of 30
cyclized to give 31 in 39% yield, as a 2:1 mixture of two diastereomers and finally after
6 steps provided them cycloproparadicicol (32).
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Unfortunately, radicicol (1) exhibited no in vivo activity, which might be due to
the highly sensitive functionality present in the molecule, including an epoxide and a
conjugated dienone, both of which are readily metabolized. As a result, significant efforts
have focused on synthesizing radicicol (1) analogs, which retain the potency, but with
improved metabolic stability (Figure 3).
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Triazole derivative (35) was synthesized by a copper-mediated cycloaddition between
benzyl azide 43 and alkyne 41, prepared from 40 in 8 steps, gave triazole 45 in near
quantitative yield. Base-promoted formation of the macrocycle and subsequent depro-
tection afforded the RAL triazole 35 in an efficient and highly convergent synthetic route
(Scheme 8). Despite the additional H-bonding potential, a decrease in Hsp90 inhibition
activity was observed (IC50 = 400 nM for 35 vs. 20–23 nM for radicicol (1)), although the
compound displayed significant in vivo activity. In a similar manner, the Danishefsky
group incorporated a triazole ring into RAL analogs, whilst retaining the carbonyl at the
9-position. None of the triazole-containing analogs displayed significant activity [32].
A synthesis of resorcylic acid macrolactam analogs of the natural product radicicol (1)
is described in which the key steps are the acylation and ring opening of a homophthalic
anhydride to give an isocoumarin, followed by a ring-closing metathesis to form the
macrocycle. Synthesis of macrolactam analogs of radicicol reported by Moody group in
2014 [33].
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The macrolactams were indeed more metabolically stable (43% metabolism for mac-
rolactam 50 vs. 84% for radicicol (1) after 15 min with human liver microsomes and 
NADH/NADPH) and, significantly, were also often superior to the corresponding other 
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2.1.3. Biological Activities of Hypothemycin (2) and LL-Z1640-2 (3) 
c e e 9. S t esis f acr lacta a al (49–52) [33].
The macrolactams were indeed more metabolically stable (43% metabolism for macro-
lactam 50 vs. 84% for radicicol (1) after 15 min with human liver microsomes and
NADH/NADPH) and, significantly, were also often superior to the corresponding other
natural macrolactones in terms of activity [34].
2.1.3. Biological Activities of Hypothemycin (2) and LL-Z1640-2 (3)
Hypothemycin (2) is a cis-enone containing natural macrocylic resorcylic acid lactone,
which is an antifungal metabolite isolated from Hypomyces trichothecoides. A comprehensive
study conducted by groups of Tanaka and Sonoda reported that treatment of hypothemycin
(2) on v-KRAS-transformed NIH3T3 (DT cells) dramatically decreased the amount of cyclin
D1 protein [35,36]. The groups also suggested cyclin D1 as a key molecule involved in
RAS downstream signaling and hypothemycin (2) might act as a RAS-signaling pathway
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inhibitor by facilitating ubiquitinating process of cyclin D1 in DT cells. Another study
of hypothemycin (2) on its kinase specificity revealed that most kinases inhibited by
hypothemycin (2) contained a conserved cysteine residue at kinase active site, which is
corresponding to the cysteine 166 of ERK1/2 and they were inhibited in a time-dependent
manner suggesting covalent inhibition of the kinases through the formation of a Michael
adduct [37]. Particularly, hypothemycin (2) displayed low nanomolar Ki values against five
kinases (MEK1, MEK2, FLT1, and KDR) and high nanomolar Ki values on TRKB. These
findings furnished explanations of the behavior of hypothemycin (2) as a RAS-signaling
pathway inhibitor [36]. Moreover, it is also of significance that hypothemycin (2) could not
inhibit GSK3β, which possesses a conserved cysteine [37].
LL-Z1640-2 (3), also known as C292 and 5-(Z)-7-oxozeaenol), is a radicicol-related
anti-protozoan isolated from an unidentified fungi source. LL-Z1640-2 (3) can selectively
inhibit transforming growth factor (TGF)-β-activated kinase 1 (TAK1) with high potency
(TAK1, IC50 = 8.1 nM) [38]. TAK1 belongs to the upstream of mitogen-activated protein
kinases (MAPK) called MAPKK-K family. TAK1 is mainly involved in the activation of JNK
and P38 MAPK by activating the following MKKKs: MKK3, MKK4, MKK6, and MKK7.
LL-Z1640-2 (3) strongly inhibited JNK/p38 pathway, however, it did not display any
effect on ERK kinase activation induced by epidermal growth factor (EGF) in Hela cells.
This provided evidence that LL-Z1640-2 (3) does not directly block JNK/p38 pathway,
but rather acts at the upstream of the MAPKK level. The JNK/P38 pathways are important
in biological responses such as inflammation, apoptosis, and cell differentiation and their
aberration might bring about diseases related to inflammatory disease, neurodegenerative
disorder, and cancer progression [39]. Therefore, LL-Z1640-2 (3) is regarded as a potential
therapeutic agent to treat such diseases and can also be used as a great toolbox for signal
transduction research [40].
2.1.4. Chemistry of Hypothemycin (2) and LL-Z1640-2 (3)
The first total synthesis of LL-Z1640-2 (3) was reported by Tatsuta and co-workers in
2001 [41]. Their synthesis commencing from the addition of tris-MOM-protected D-ribose
53 and lithiated TMS-acetylene to propargylic alcohol 54 followed by protection, which
was then undergone a Sonagashira reaction to aromatic iodo 55 to get 56 and after 6 steps
generate propargylic alcohol 57 (Scheme 10). Target structure produced by a Mukaiyama
macrolactonization reaction of a protected seco acid 58 in 3% overall yield for the longest
linear sequence of 19 steps (from D-ribose).
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(2) and LL-Z1640-2 (3) would be constructed either through Mitsunobu-based macrolac-
tonization from seco acid 59 or, alternatively, through a Suzuki-type macrocyclization of
ester 60. Both 59 and 60 would be derived from o-bromo benzoic acid 61 and intermediate
62 (Figure 5). The synthesis developed by Selles and Lett provided LL-Z1640-2 (3) and
hypothemycin (2) in overall yields of 1% and 0.17%, respectively, in 26 steps for the longest
linear sequence.
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In 2010, Barrett group reported total synthesis of LL-Z1640-2 (3) via consecutive mac-
rocyclization and transannular aromatization [45]. According to their synthetic protocol 
thermolysis of diketo-dioxinone 71 resulted in generation of ketene intermediate, which 
was efficiently trapped intramolecularly by the alcohol to provide the 18-membered mac-
rocyclic lactone 72 (Scheme 13). Regioselective methylation, followed by deprotection and 
oxidation gave LLZ1640-2 (3) in 51% yield over three steps. 15-step biomimetic total syn-
thesis of the TAK-kinase inhibitor LL-Z1640-2 (3) from commercially available starting 
materials was reported. 
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Total synthesis of LL-Z1640-2 (3) utilizing a late-stage intramolecular Nozaki–Hiyama–
Kishi reaction was reported by Thomas et al. in 2010 [44]. Their route depended on an
aryl selenide nucleophile for a precedented sequence of alkylation, oxidation, and elimi-
nation to generate the requisite trans-olefin scaffold (Scheme 12). Subsequent Mitsunobu
esterification would provide access to an advanced intermediate 68 and 69 poised for
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macrocyclization with the intramolecular Nozaki–Hiyama–Kishi (NHK) reaction. Finally,
oxidation and deprotection completed natural product LL-Z1640-2 (3) synthesis.
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a common benzylic sulfide intermediate to access both LL-Z1640-2 (3) and hypothemycin
(2) [47]. Starting from resin-bound intermediate 75, the toluate position was alkylated with
iodide 76 to obtain polymer-bound intermediate 77 (Scheme 15). Mitsunobu cyclisation
followed by the release of sulfur resin under oxidative condition gave 78 which was
oxidized to the desired cis-enone under slightly more forceful conditions by using DMP in
CH2Cl2 under reflux and led to final compounds both natural products LL-Z1640-2 (3) and
hypothemycin (2).
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In 2009, a serum and plasma-stable resorcylic acid analog of ER-803064 (79) was
discovered [48]. The addition of the (S)-Me group at C4 has resulted in a dramatic improve-
ment in metabolic stability with retention of bioactivity (Scheme 16). Aromatic ester 80
and aliphatic iodo 81 were coupled and further steps were employed to get aldehyde 82 in
5 steps which after 8 synthetic steps gave final ER-803064 (79).
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In 2014, synthesis and biological studies of a triazole analogue (90) of LL-Z1640-2 (3) 
were reported by the Chen group in 6 linear steps in 18% overall yield [50]. The triazole 
analog (90) showed good activity (IC50 = 7.2 μM) against MNK2 kinase, which is an emerg-
ing target for cancer chemotherapy (Scheme 18). Azido intermediate 91 which was syn-
thesized from 2-deoxy d-ribose acetonide and phloroglucinol carboxylic acid treated with 
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In 2010, the Wang group reported a potent in vitro lead compound, 83 and 84, fully syn-
thetic analogs of natural product LL-Z1640-2 (3). The analog 84 maintained the metabolic
stability, regained full in vitro potency similar to natural product, and had significant
improvement in in vivo potency (Scheme 17). Their synthesis started from commercially
available methyl orsellinate (85) and after 5 steps afforded aromatic selenide intermediate
86 which was then coupled with acyclic iodide in the presence of LiHMDS followed by
mCPBA oxidation, TBAF deprotection, and lactone cyclization under the influence of
Mukaiyama’s reagent to provide lactone 87. Deprotection followed by C14 substitutions
was done through Mitsunobu reaction and benzoyl group was then deprotected under
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basic conditions to produce allylic alcohol 11. Finally, oxidation followed by deprotection
led to final analog 83 and 84 [49].
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ing target for cancer chemotherapy (Scheme 18). Azido intermediate 91 which was syn-
thesized from 2-deoxy d-ribose acetonide and phloroglucinol carboxylic acid treated with 
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led to a smooth click reaction to afford the desired triazole 92 followed by successful
macrocyclization and intramolecular transesterification with NaH. Final deprotection of
the acetonide 93 concluded a concise synthesis of the triazole analog 90.
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In 2016, an efficient synthesis of an exo-enone analog (94) of LL-Z1640-2 and eval-
uation of its protein kinase inhibitory activities were reported by the Chen Group [51].
The synthesis has been achieved using a Ni-catalyzed regioselective reductive coupling
macrocyclization of an alkyne–aldehyde as a key step (Scheme 19). The synthesis of 94
commenced with the reported intermediate alkene 95 which after protection and trans-
est rification in the presence of NaH gave intermediate 96 in nearly quantitative yield.
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Alkyne–aldehyde 97 was readily synthesized in 3 steps from 96. As per reported condition
97 under moderate dilution (0.013 M), gratifyingly provided the desired macrocyclization
product 98 in 57% isolated yield. This reaction proceeds via an alkenylnickel species formed
by a regioselective hydronickelation of the alkyne. Finally, oxidation and deprotection
furnished the required exo-enone analog 94.
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2.1.5. Biological Activities of L-783277 (4)
L-783277 (4) is a naturally occurring 14-membered resorcylic acid lactone isolated
from Helvella acetababulum, a species of fungus in the family Helvellaceae. L-783277 (4)
is especially known for its highly potent inhibitory activity against MEK (IC50 of 4 nM).
The unexceptional binding affinity of L783277 (4) to kinases is mainly due to the presence
of the electrophilic cis-enone moiety that forms Michael adducts with conserved cysteine
residue residing near the DFG motif of the kinases. As a good comparison, a C7′-C8′
trans-enone analog of L-783277 (4), exhibited 75-fold decreased activity against MEK (IC50
of 300 nM). Moreover, L-783277 (4) was reported to possess potent inhibitory activities
against several kinases including VEGFR2/3, FLT1/3/4, MEK1/2, KDR, and PDGFRα but
with low kinome selectivity [47,52].
We investigated the effects of a structural nature of L-783277 (4) on kinase inhibitory
activities in three subsequent researches [52–54]. In an effort to expand our MEK kinase
program and to conduct a detailed SAR study with L-783277 (4) derivatives, we devel-
oped an efficient synthetic route toward L-783277 (4) [54]. With this effective synthetic
approach distinctive from those reported in precedent literature at the time, we were able
to obtain tens of milligrams of L-783277 (4) by simple purification method using flash silica
chromatography [47,55].
We noticed an observation that hypothemycin (2) could not inhibit GSK3β possessing
a conserved cysteine while it could inhibit kinases without conserved cysteines (Src, TrkA,
and Trk) [37]. Accordingly, we further investigated the structure of L-783277 (4), based
on our postulation that the reversible binding of RALs might also play a key role in
determining the inhibitory activities and overall selectivity toward kinases. To test the
hypothesis, we synthesized a reversible version of L-783277 (4), 99, in which the alkene
moiety of the cis-enone of L-783277 (4) was saturated and a number of analogs derived from
99 (Figure 6). Kinome-wide selectivity profiling and biochemical assays were conducted
with 99 and results showed that 99 inhibits activin A-like kinase 1 (ALK1) more potently
than its parent compound, L-783277 (4), does and it displayed a better kinase selectivity
against a panel of 342 kinases. ALK1 is a serine threonine kinase expressed predominantly
in endothelial cells and it functions as a receptor for bone morphologic protein 9 (BMP9).
Binding of the ligand to ALK1 activates Smad4 by phosphorylating Smad1/5/8, which
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upregulates transcription of various target genes involved in angiogenesis [56,57]. Due to
the significance of ALK1 in regulation of tumor angiogenesis, it has been regarded as
a potential therapeutic target for the development of anticancer agents [58]. Although
dorsomorphin and LDN193189 showed inhibitory activities against BMP type I receptor
kinase and could inhibit BMP-related Smad and non-Smad signaling, inhibitory activities
displayed by the two were so broad that it also inhibited other signaling pathways, inducing
adverse events brought by off-target effects. In this study, we reported that 99 is a potent
and selective ALK1 inhibitor, which acts by selectively blocking BMP9-induced ALK1
signaling in C2C12 cells [52]. It is also highly noteworthy that ALK1 is one of the kinases
that has no conserved cysteine residue equivalent to Cys168 of ERK2. Therefore, the
selectivity of 99 is achieved by its inability to form a Michael adduct with the most kinases.
Moreover, greater conformational flexibility of 99 enables it to adopt superior binding
mode, which is the reason that the 99 shows higher activity relative to L-783277 (4) against
ALK1 (IC50 ALK1 = 62 nM and 126 nM for 99 and L-783277 (4), respectively).
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Our experience in discovering the first reversible version of L-783277 (4) as a potent
and selective ALK1 inhibitor encouraged us to focus on further development of L-783277 (4)
analogs with increased kinome-wide selectivity. We previously observed that L-783277 (4)
strongly inhibited VEGFR3/2 and FLT3 but it displayed poor kinome-wide selectivity. The
tyrosine kinase vascular endothelial growth factor receptor3 (VEGFR3) and its homolog,
VEGFR2, take part in tumor lymphangiogenesis [59] and angiogenesis [60], respectively.
Because inhibiting both angiogenesis and lymphangiogenesis is claimed to be a reasonable
strategy to treat cancer [61,62], we aimed to discover novel L-783277 (4) derivatives that
selectively inhibit VEGFR2/3 and FLT3 with high potency. Our strategy implemented in
order to achieve this goal was to rigidify the structure of 14-membered lactone scaffold of
L-783277 (4), anticipating that structural rigidity could potentially enhance kinome-wide
selectivity of L-783277 (4). We synthesized 11 novel L-783277 (4) derivatives containing
a phenyl ring incorporated in the 14-membered chiral resorcylic acid lactone ring system
to assess this hypothesis. Among these derivatives, 100 exhibited the highest potencies
against VEGFR3, VEGFR2, and FLT3 and excellent kinome-wide selectivity [54]. Moreover,
results of corneal assay conducted with 100 demonstrated effective suppression of both
lymphangiogenesis and angiogenesis, indicating that 100 is a potential and unique template
to be used in the development of therapeutically active and selective compound, targeting
both lymphangiogenesis and angiogenesis [54].
Most natural macrocyclic lactones exert physiological effects by covalently binding
to vari us biological targets. This, however, is often regarded as a major reason behi d
poor selectivity among sub trates and undesired dose-depen ent toxicities. Our findings
obtain d during the course of structural modification an biological evaluation of L-783277
(4) indicate that simple transformation made on a macrocyclic lactone can dramatically
increase substrate specificity and potency against a cert in protein of interest. It is also of
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significance that exploration of such an effort was firstly demonstrated by our group [52,54].
Furthermore, we anticipate that our works on L-783277 (4) and its derivatives (99 and 100)
provide a promising basis for further developments of natural and synthetic lactones, along
with other natural products, as potential anticancer agents.
2.1.6. Chemistry of L-783277 (4)
The first synthesis of L-783277 (4) was achieved by Altmann et al. in 2008, through the
successful exploration of Suzuki coupling and a late-stage macrolactonization reaction [55].
Their synthesis commenced from isopropylidene-D-erythrono-1,4-lactone 101 as a chiral
starting material to intermediate 102 in 10 steps with 27% yield (Scheme 20). TMS-ethyl
ester was obtained from the corresponding methyl ester 103 via ester cleavage with TMSOK
under microwave conditions followed by Suzuki coupling with 102 gave 104 in 60% yield.
Hydrogenation of 104 under Lindlar condition and deprotection gave the seco acids 105
in good yield. Cyclization under Mitsunobu conditions followed by deprotection and
oxidation with polymer-bound IBX led to a mixture of L-783277 (4) and a second mono-
oxidized product whose exact structure was uncertain, separated by flash chromatography.
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Toluate position of resin-bound 111 was alkylated with iodide 110 to obtain polymer-
bound intermediate 112 followed by removal of the PMB and the TMSE. Macrolactoniza-
tion under Mitsunobu conditions followed by reductive conditions to get macrocycle 113 
after benzoate hydrolysis (Scheme 22). The natural products L-783277 (4) could be ob-
tained by straightforward diazomethane treatment of compounds 114 (>90% conversion 
based on LC/MS, 63–74% isolated yield after HPLC purification). It should be noted that 
their final product isolated by HPLC were typically contaminated with small amounts 
(>5%) of a side product that is tentatively ascribed to the trans-enone isomer. 
Sche e 20. First total synthesis of L-783277 (4) by Alt ann et al. [55].
In 2009, the Winssinger Group reported the synthesis of L-783277 (4) together with
the synthesis of LL-Z1640-2 (3), and hypothemycin (2) as a part of their divergent synthetic
approach towards resorcylic acid lactones [47]. According to their synthetic route, vinyl
bromide 107 could be obtained in 4 steps from the less expensive methyl 3-hydroxybutyrate
106 (Scheme 21). Another commercially available protected deoxyribose 108 was converted
to protected aldehyde 109 in 3 steps which was further converted to intermediate 110 in
4 synthetic steps with 72% yield.
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Toluate position of resin-bound 111 was alkylated with iodide 110 to obtain polymer-
bound intermediate 112 followed by removal of the PMB and the TMSE. Macrolactonization
under Mitsunobu conditions followed by reductive conditions to get macrocycle 113 after
benzoate hydrolysis (Scheme 22). The natural products L-783277 (4) could be obtained by
straightforward diazomethane treatment of compounds 114 (>90% conversion based on
LC/MS, 63–74% isolated yield after HPLC purification). It should be noted that their final
product isolated by HPLC were typically contaminated with small amounts (>5%) of a side
product that is tentatively ascribed to the trans-enone isomer.
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c e e 23. Synthesis of frag ent 118 by Si et al. [53].
D-(R)-glyceraldehyde acetonide 120 was prepared from D-mannitol 119 in two steps
according to the literature meth d [63]. The asymmetric Brown allylat on of aldehyde 120
using (−)-Ipc2BOMe yielded the desired allylic alcohol 121 i high diastereoselectivity
(92:8) (Scheme 24). The depro ection of the acetonide group ge erated 122 and protection
of TBDPS and acetonide then produced fragment 123 in 38% yield from glyceraldehyde.
The preparati of thi d alkyne fragment 124, comm nced with omm rcially
available (S)-(−)-propylene oxide 125, which underwent ready conversion into secondary
alcohol 126 upon treatment with lithium trimethylsilylacetylene (Scheme 25). Protection
and deprotection gave us alkyne fragment 124 with a 93% yield in 2 steps.
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Olefin cross metathesis strategy between fragments 118 and 123 using Grubbs 2nd
generatio atalyst furnished the st rene 127 (cis:trans = 3:7) which hydrogenated to get
128 (Scheme 26). The trans sterificatio of the compound was conducted with NaOMe
to provide methyl ester 129, which after prote tion and deprotection generated primary
alcohol 130 with 17% yield in 5 steps.
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Sche e 26. Synthesis of frag ent 130 by Si et al. [53].
The primary alcohol 130 was smoothly oxidized to the corresponding aldehyde and
attacked by lithium acetylide to afford allylic alcohol 131 in 42% yield over two steps
(Scheme 27). Hydrogenation reaction using Lindlar catalyst to give the corresponding
cis-olefin 132, which after protection and deprotection generate 133 with 86% yield in
3 steps. Saponification followed by cyclization under Mukaiyama condition generated 134
in moderate yield. Finally, deprotection followed by oxidation and global deprotection
furnished natural product L-783277 (4) with 63% yield in 3 steps.
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Sulfone 139 and aromatic aldehyde 140 was then subjected to JK olefination to furnish
the ‘E’-olefin 142 in 78% yield which after 3 steps gave aldehyde intermediate 143 with 73%
yield (Scheme 30).
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Alkyne 144 which was obtained through nucleophilic addition reaction of 143 with
alkyne 145, after 5 steps gave 146 with 45% yield in 5 steps. Deprotection and oxidation
then furnished natural product L-783277 (4) with 47% yield in 3 steps (Scheme 31).
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A trans-isomer of L-783277 (4) was also isolated but RALs bearing the cis-enone moiety
such as hypothemycin (2), LL-Z1640-2 (3), and L-783277 (4) are more potent than the
trans-enone L-783290 (147) (Figure 7). Banwell’s group reported the first synthesis of
L-783290 (147, the E-counterpart of L-783277 (4), Figure 6) through the exploitation of
Heck coupling and intramolecular Weinreb ketone synthesis followed by other synthetic
manipulation [65].
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A chemoenzymatic pathway was employed where they used enantiomerically pure
and commercially available cis-1,2-dihydrocatechol 148 derived from the whole-cell bio-
transformation of chlorobenzene to get Weinreb amide fragment 149 in 7 steps (Scheme 32).
The reaction of commercially available dimethoxyaniline 150 to a Sandmeyer reaction
followed by Vilsmeier–Haack conditions afforded benzaldehyde 152 in 2 steps with 44%
yield (Scheme 33).
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The Heck coupling reaction of aryl iodide 152 and terminal alkene 149 gave 153,
which after 2 steps produced 154 for a Mitsunobu reaction with 155 to give ester/amide
156, which was treated with Grignard reagent to get 157. Finally, Grubbs metathesis and
deprotection furnished target macrolide 147 in 10% yield (Scheme 34).
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5′-Deoxy analog (158) of L-783277 (4) was synthesized stereoselectively in 2011 by
Altmann group [66]. This analog retains almost the full kinase inhibitory potential of
natural L-783277 (4), with low nanomolar IC50 values against the most sensitive kinases,
and it exhibits essentially the same selectivity profile (within the panel of 39 kinases
investigated). In contrast, removal of both the 4′- and the 5′-hydroxyl groups leads to a
more significant reduction in kinase inhibitory activity.
Int. J. Mol. Sci. 2021, 22, 1052 21 of 67
Intermediate 160 was prepared from TBS-protected 3-hydroxy propanal 159 in a high-
yielding four-step sequence (69% overall yield) involving Keck allylation (Scheme 35). After
some synthetic steps, intermediate 160 was converted to 161, which was coupled with
aromatic fragment 162 by Suzuki coupling to get 163. Mitsunobu cyclization, protection,
deprotection steps were used to furnished 5′-deoxy analog (158) of L-783277 (4) in 4 steps.
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Scheme 35. Synthesis of 5′-deoxy analogue (158) by Altmann et al. [66].
Our group synthesized a saturated analog (99) of L-783277 (4) [52]. Our synthetic
route comprises three key steps involving a Suzuki cross-coupling reaction between an
aromatic triflate and olefin, the addition of an acetylene to an aldehyde, and Mitsunobu
macrolactonization (Scheme 36). Triflate 164 and olefin 165, prepared from commercially
available 2,4,6-trihydroxybenzoic acid and 1,2,5,6-bis-O-(1-methylethylidene)-D-mannitol,
respectively (structures not shown), would be joined by the use of a Suzuki cross-coupling
reaction to produce the key intermediate 166.
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The propargylic alcohol 167 was prepared from 166 using the same sequence of
reactions described in our previous report [53]. Lindlar hydrogenation, deprotection,
and saponification generated seco acid 168, which was cyclized under Mitsunobu condition
to deliver a diastereomeric mixture of 169 (Scheme 37).
Oxidation of a mixture 169 gave pure keto derivative which after final deprotection
furnished target lactone 99 (Scheme 38). It is noteworthy to mention that advanced inter-
mediates 169 and 170 in the route for synthesis of 99 were also used for preparation of
the trihydroxy analogs of L-783277 (4), 171, 172, and external olefin containing analog 173
(Scheme 38).
Next, we synthesized phenyl ring incorporated derivatives of L-783277 (4) in ex-
pectation that these derivatives would improve kinome-wide selectivity of the parent
compound 4 [54]. The key reactions employed in the synthetic sequences are Suzuki
coupling, Sharpless asymmetric dihydroxylation, alkyne addition to an aldehyde, Lindlar
reduction, and Mitsunobu cyclization.
Int. J. Mol. Sci. 2021, 22, 1052 22 of 67




Scheme 37. Synthesis of intermediates 169A and 169B by Sim et al. [52]. 
Oxidation of a mixture 169 gave pure keto derivative which after final deprotection 
furnished target lactone 99 (Scheme 38). It is noteworthy to mention that advanced inter-
mediates 169 and 170 in the route for synthesis of 99 were also used for preparation of the 
trihydroxy analogs of L-783277 (4), 171, 172, and external olefin containing analog 173 
(Scheme 38). 
 
Scheme 38. Synthesis of analogs (99, 172–173) from intermediates 169A and 169B by Sim et al. [52]. 
Next, we synthesized phenyl ring incorporated derivatives of L-783277 (4) in expec-
tation that these derivatives would improve kinome-wide selectivity of the parent com-
pound 4 [54]. The key reactions employed in the synthetic sequences are Suzuki coupling, 
Sharpless asymmetric dihydroxylation, alkyne addition to an aldehyde, Lindlar reduc-
tion, and Mitsunobu cyclization.  
Our route began with Suzuki coupling between triflate 174 and boronic acid 175 to 
produce biphenyl derivative 176 firstly (Scheme 39). Oxidation followed by Wittig ole-
fination formed trans form of 177. Sharpless asymmetric dihydroxylation followed by pro-
tection and trans-esterification produced 178 in 4 steps which after 4 synthetic steps pro-
duced 179. PMB-ether protection followed by TBS-ether deprotection then generated 180 
in 2 steps, the important cyclization precursor.  
c . t esis f i ter e i tes i et l. [ ].




Scheme 37. Synthesis of intermediates 169A and 169B by Sim et al. [52]. 
Oxidation of a mixture 169 gave pure keto derivative which after final deprotection 
furnished target lactone 99 (Scheme 38). It is noteworthy to mention that advanced inter-
mediates 169 and 170 in the route for synthesis of 99 were also used for preparation of the 
trihydroxy analogs of L-783277 (4), 171, 172, and external olefin containing analog 173 
(Scheme 38). 
 
Scheme 38. Synthesis of analogs (99, 172–173) from intermediates 169A and 169B by Sim et al. [52]. 
Next, we synthesized phenyl ring incorporated derivatives of L-783277 (4) in expec-
tation that these derivatives would improve kinome-wide selectivity of the parent com-
pound 4 [54]. The key reactions employed in the synthetic sequences are Suzuki coupling, 
Sharpless asymmetric dihydroxylation, alkyne addition to an aldehyde, Lindlar reduc-
tion, and Mitsunobu cyclization.  
Our route began with Suzuki coupling between triflate 174 and boronic acid 175 to 
produce biphenyl derivative 176 firstly (Scheme 39). Oxidation followed by Wittig ole-
fination formed trans form of 177. Sharpless asymmetric dihydroxylation followed by pro-
tection and trans-esterification produced 178 in 4 steps which after 4 synthetic steps pro-
duced 179. PMB-ether protection followed by TBS-ether deprotection then generated 180 
in 2 steps, the important cyclization precursor.  
. , i t r i t s a 169 Si et al. [52].
Our route began with Suzuki coupling between triflate 174 and boronic acid 175
to produce biphenyl derivative 176 firstly (Sche e 39). Oxidation followed by Wittig
olefination formed trans form of 177. Sharpless asymmetric dihydroxylation followed by
protection and trans-esterification produced 178 in 4 steps which after 4 synthetic steps
produced 179. PMB-ether protection followed by TBS-ether deprotection then g nerated
180 in 2 steps, the important cyclization precursor.
Subsequ ntly, 180 un erwent saponificati n followed by cyclization under M tsunobu
condition and deprotection to get 181 in 3 synthetic steps with good yield (Scheme 40).
Oxidation of 181 formed the corresp nding ketones 182 as a si gle st reoisomer, which
was finally deprot cted to form target 100. Oth r derivatives lso w s nthesized by using
a similar synthetic strategy to expand the scope of the SAR study.
2.2. Sesquiterpene Lactones
Sesquiterpene lactones (SLs) are a sub-class of sesquiterpenoids, which are natural
products synthesized in several organs of plants such as leaves, shoots, and roots [67,68].
In addition, SLs comprise a large and diverse group of secondary metabolites isolated
from diverse plant families [69,70] with the greatest number occurring in members of
Asteraceae [69–71]. Extracts of SLs, like other natural products, have been broadly used in
folk medical practices for fever, headache, rheumatoid arthritis, and menstrual irregular-
ities [72]. SLs are usually characterized by the presence of α-methylene-γ-lactone group
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(αMγL), which mainly contributes to the underlying biological activity of SLs through
irreversibly forming a Michael adduct with nucleophilic amino acid residues in proteins,
causing alterations in protein activity [73]. This is regarded as the primary mechanism of
cytotoxicity induced by SLs (Figure 8).




Scheme 39. Synthesis of the cyclization precursor 180 by Sim et al. [54]. 
Subsequently, 180 underwent saponification followed by cyclization under 
Mitsunobu condition and deprotection to get 181 in 3 synthetic steps with good yield 
(Scheme 40). Oxidation of 181 formed the corresponding ketones 182 as a single stereoi-
somer, which was finally deprotected to form target 100. Other derivatives also we syn-
thesized by using a similar synthetic strategy to expand the scope of the SAR study. 
 
Scheme 40. Synthesis of rigidified analogue of L-783277 (100) by Sim et al. [54]. 
2.2. Sesquiterpene Lactones 
Sesquiterpene lactones (SLs) are a sub-class of sesquiterpenoids, which are natural 
products synthesized in several organs of plants such as leaves, shoots, and roots [67,68]. 
In addition, SLs comprise a large and diverse group of secondary metabolites isolated 
from diverse plant families [69,70] with the greatest number occurring in members of 
Asteraceae [69–71]. Extracts of SLs, like other natural products, have been broadly used 
in folk medical practices for fever, headache, rheumatoid arthritis, and menstrual irregu-
larities [72]. SLs are usually characterized by the presence of α-methylene-γ-lactone group 
(αMγL), which mainly contributes to the underlying biological activity of SLs through 
irreversibly forming a Michael adduct with nucleophilic amino acid residues in proteins, 
causing alterations in protein activity [73]. This is regarded as the primary mechanism of 
cytotoxicity induced by SLs (Figure 8). 
Schem 39. Synthesi of the cycli precursor 180 by Sim et al. [54].




Scheme 39. Synthesis of the cyclization precursor 180 by Sim et al. [54]. 
Subsequently, 180 underwent saponification followed by cyclization under 
Mitsunobu condition and deprotection to get 181 in 3 synthetic steps with good yield 
(Scheme 40). Oxidation of 181 formed the corresponding ketones 182 as a single stereoi-
somer, which was finally deprotected to form target 100. Other derivatives also we syn-
thesized by using a similar synthetic strategy to expand the scope of the SAR study. 
 
Scheme 40. Synthesis of rigidified analogue of L-783277 (100) by Sim et al. [54]. 
2.2. Sesquiterpene Lactones 
Sesquiterpene lactones (SLs) are a sub-class of sesquiterpenoids, which are natural 
products synthesized in several organs of plants such as leaves, shoots, and roots [67,68]. 
In addition, SLs comprise a large and diverse group of secondary metabolites isolated 
from diverse plant families [69,70] with the greatest number occurring in members of 
Asteraceae [69–71]. Extracts of SLs, like other natural products, have been broadly used 
in folk medical practices for fever, headache, rheumatoid arthritis, and menstrual irregu-
larities [72]. SLs are usually characterized by the presence of α-methylene-γ-lactone group 
(αMγL), which mainly contributes to the underlying biological activity of SLs through 
irreversibly forming a Michael adduct with nucleophilic amino acid residues in proteins, 
causing alterations in protein activity [73]. This is regarded as the primary mechanism of 
cytotoxicity induced by SLs (Figure 8). 
e e 40. Synthesis of rigidified analogue of L- 83277 (100) by Sim et al. [54].




Figure 8. Structures of representative sesquiterpene lactones. 
2.2.1. Biological Activities of Parthenolide (183) 
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2.2.2. Chemistry of Parthenolide (183)
The first total synthesis of parthenolide (183) and its analogs was reported by Long
and co-workers in 2014 [90]. In their initial retro-synthetic analysis of parthenolide (183)
(Scheme 41), it was anticipated that parthenolide (183) could be obtained by the known
compound 191 through three key intermediates. The crucial reaction step conceived by
Long et al. for the target molecule included intramolecular Barbier-type cyclization of B to
form A [91], which then undergoes lactonization to generate parthenolide (183).
The primary attempt of the group to synthesize parthenolide (183) is summarized
in Scheme 42. The synthesis was initiated with known compound 191, which was ob-
tained from farnesol in three steps [92]. 191 was treated with methyl acrylate and 1,4-
diazabicyclo[2.2.2]octane (DABCO) to produce substituted acrylate 192. This was followed
by chlorination with simultaneous double bond isomerization to provide only (Z)-193
and TBDPS was deprotected by using HF-pyridine. It should be noted that TDBPDS
deprotection of 193 did not proceed under standard TBAF or TFA conditions [90]. The pri-
mary alcohol of 193 underwent Sharpless asymmetric oxidation (SAE) reaction to yield
compound 194, which was subsequently oxidized to give corresponding aldehyde 195.
Authors have investigated the cyclization of 195 by means of reductive Barbier-type cou-
pling conditions to form the desired 10-membered ring. Under CrCl2 in degassed DMF,
amongst other conditions, such as Zn0, In0, and SmI2, only gave out the cyclized product
196. Unfortunately, the lactone 196 was revealed to be the C-7 epimer of parthenolide (183)
after an analysis of X-ray co-crystal data [90].
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Long et al. have designed and synthesized cyclization precursors 197a and 197b
via 8 steps, based on their speculation that the configuration of the two new stereogenic
centers might be highly affected by the geometric configuration of 1,10-double bond
(Scheme 43) [90]. From nerol, compound 198 was obtained in 5 steps [93,94]. After pro-
tecting alcohol of 198 with TBDPS, C10-C11 double bond was cleaved to afford aldehyde
199, which underwent Baylis–Hillman reaction, then chlorination to produce 200a and
200b in 3:1 ratio. Lastly, 200a and 200b were used to obtain the cyclization precursors
197a and 197b. A reaction condition of an umpolung allylation optimized by Baran et al.
was utilized in the transformation of 197a to 6,7-cis 201 and the desired 6,7-trans 202 in a
ratio of 2.8:1 in 16% yield [95]. Surprisingly, the ratio of 6,7-trans 202 reaction yield was
much improved when the relatively low reactive allylic chloride was converted into allylic
iodide prior to Barbier reaction using CrCl2 in THF. This two-steps procedure produced an
increased ratio f 6,7-trans 202 (1:1) and a moderate yield (52%) [90].
Scheme 44 provided the target compound parthenolide (183). Hydrolysis of 201 and
202 by using basic hydrogen peroxide produced compounds 203, 204, and 205 (Scheme 44).
Lactone 206 was obtained by refluxing compound 203 in benzene with DBU. Moreover,
another side product 204 could be converted to the desired intermediate 205 upon stirring
with DBU in CH2Cl2. The target molecule 183 was successfully obtained upon irradiating
205 with UV light (254 nM) in 58% conversion and 77% yield [90].
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Overall, Long et al. have demonstrated the first effective synthetic route, which can be
used to synthesize parthenolide (183) and its analogs. Moreover, insights acquired from
this investigation on synthetic routes of parthenolide (183) may provide general strategies
to synthesize trans-germacronolide analogs with high m dical relevance.
I an effort to overcome poor water solubility of parthenolide (183) without compro-
mising its anti-leukemic activity, Neelakantan and coworkers carried out the synthesis
and structure-activity relationship studies of a series of aminoparthenolide analogs deriv-
ied from various aliphatic primary and secondary amines [88]. It is of significance that
R-configuration at the newly formed C-11 chiral center was conserved after the Michael-
type addition of parthenolide (183) with aliphatic amines (Scheme 45). Authors have
concluded that the protonation of the enolate formed during the reaction, which occurs
from the exo face of the molecule, causes the conservation of R-conformation at C-11 in the
product. During the course of investigation, dimethylamino analog (190) was identified
as the representative compound exhibiting significant anti-leukemic activity in the AML
assay [88]. However, aminoparthenolide analogs showed low metabolic and chemical
stability. Especially, it was prone to the cytochrome P450 (CYP450)-catalyzed oxidation,
which significantly decreases the bioactivity of the compound [96]. Therefore, additional
research to reduce the effect of CYP450-catalyzed oxidation was necessitated.
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(a) dimethylamine, MeOH, rt; (b) Fumari aci , diethyl ether [88].
In addition, Yang et al. reported the asy etric total synthesis of ger acrane ring
207, inspired by the biosynthetic route of sesquiterpene lactones (Figure 10) [97]. A ore
detailed description on the synthetic route used to afford the germacrane ring 207 will
be provided in the chemistry of costunolide (186) section (see Section 2.2.8). The key
intermediate 207 can be served as a great starting point to prepare the natural lactones
parthenlide (183) and costunolide (186).
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metabolic stability equivalent to that of parthenolide (183) [97].
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2.2.3. Biological Activities of Alantolactone (184) 
Alantolactone (184) is a potent anticancer compound for various tumor cells, which 
is mainly obtained from the medical herb Inula helenium [101–103]. However, the under-
lying mechanism of anti-cancer activity of alantolactone (184) is still not clearly deter-
mined. Liu et al. investigated antiangiogenic effect alantolactone and its molecular mech-
anism. Alantolactone (184) exhibits an IC50 value of 40 μM against MDA-MB-231 cells and 
14.2 μM against human umbilical vein endothelial cells (HUVEC) cells. This indicates se-
lective nature of alantollactone (184) on active endothelial cells. VEGFR2 phosphorylation 
plays a key role in tumor angiogenesis and authors demonstrated alantolactone (184) sup-
presses VEGFR2 phosphorylation and its downstream signals, including PLCγ1, FAK, 
Src, and AKT [104]. Hence, alantolactone (184) can work as a VEGFR2 inhibitor and ex-
hibit antiangiogenic activity. Xing Kang et al. suggested in their study of alantolactone 
(184) on HepG2 (description) that ROS-AKT pathway might participate in apoptosis in-
duced by alantolactone (184) [105]. In addition, alantolactone (184) can penetrate the blood 
brain barrier (BBB) and act as a therapeutic agent for CNS neoplasm. Alantolactone (184) 
induces apoptosis in glioblastoma cells by inhibiting NFkB/COX-2 signaling pathway. Ex-
pression of COX-2 in glioblastoma cells was suppressed mainly due to inhibition of IKKβ 
by binding of alantolactone (184) to the ATP-site [106]. 
2.2.4. Chemistry of Alantolactone (184) 
The stereoselective total synthesis of racemic alantolactone (184) was reported in 1965 
by Marshall et al. [107]. To the best of our knowledge, there were no other reports illus-
trating the enhanced synthetic approaches to alantolactone (184), but a number of groups 
have reported semi-synthetic derivatives of the natural product and their biological eval-
uation. Probably, this is because there are abundant available sources of alantolactone in 
nature, including Inula helenium L., Inula japonica, Aucklandia lappa, Inula racemosa, and so 
on, where it can be isolated at ease by means of different chromatographic techniques 
[108–111]. 
Three key reaction steps categorized by Marshall and coworkers are as follows: first, 
the construction of the carboxylic scaffold by cationic olefin cyclization (212 to 213), sec-
ondly, modification of the carbon framework to afford 222, and lastly, formation of α-
methylene-γ-butyrolactone (222 to 184). The actual synthesis of Alantolactone (184) is 
summarized in Scheme 47, commencing with unsaturated ketone 211 afforded from 4-
bromobutene in two steps [107]. Ketone 211 then was reacted with ethereal methylithium 
to give alcohol 212, which was cyclized to generate formate 213 according to a procedure 
previously developed by Johnson and co-workers for analogous compounds [112]. Alco-
hol 214 produced from saponification of the resulting formate 213 was oxidized with chro-
mic acid reagent giving octalone 215 [113]. Upon treatment of ethyl bromacetate to 215 via 
Stork enamine procedure and saponification of the crude mixture, keto acid 216 was af-
forded in 53% overall yield [107]. It should be noted that steric effects around C-9 rendered 
the alkylation difficult and thus formed Δ7-isomer more predominantly than Δ7-isomer, 
which eventually led to the formation of C-alkylation product 216 in high yield [114]. Keto 
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tions: (a) nO , C 2Cl2, r.t., 8 h, 25% over 3 steps; (b) m-CPBA, CH2Cl2, 25 ◦C, 3 h, 91%. [97].
2.2.3. Biological Activities of Alantolactone (184)
Alantolactone (184) is a potent anticancer compound for various tumor cells, which is
mainly obtained from the medical herb Inula helenium [101–103]. However, the underlying
mechanism of anti-cancer activity of alantolactone (184) is still not clearly determined.
Liu et al. investigated antiangiogenic effect alantolactone and its molecular mechanism.
Alantolactone (184) exhibits an IC50 value of 40 µM against MDA-MB-231 cells and 14.2 µM
against human umbilical vein endothelial cells (HUVEC) cells. This indicates selective
nature of alantollactone (184) on active endothelial cells. VEGFR2 phosphorylation plays a
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key role in tumor angiogenesis and authors demonstrated alantolactone (184) suppresses
VEGFR2 phosphorylation and its downstream signals, including PLCγ1, FAK, Src, and
AKT [104]. Hence, alantolactone (184) can work as a VEGFR2 inhibitor and exhibit an-
tiangiogenic activity. Xing Kang et al. suggested in their study of alantolactone (184) on
HepG2 (description) that ROS-AKT pathway might participate in apoptosis induced by
alantolactone (184) [105]. In addition, alantolactone (184) can penetrate the blood brain
barrier (BBB) and act as a therapeutic agent for CNS neoplasm. Alantolactone (184) induces
apoptosis in glioblastoma cells by inhibiting NFkB/COX-2 signaling pathway. Expression
of COX-2 in glioblastoma cells was suppressed mainly due to inhibition of IKKβ by binding
of alantolactone (184) to the ATP-site [106].
2.2.4. Chemistry of Alantolactone (184)
The stereoselective total synthesis of racemic alantolactone (184) was reported in 1965
by Marshall et al. [107]. To the best of our knowledge, there were no other reports illustrat-
ing the enhanced synthetic approaches to alantolactone (184), but a number of groups have
reported semi-synthetic derivatives of the natural product and their biological evaluation.
Probably, this is because there are abundant available sources of alantolactone in nature,
including Inula helenium L., Inula japonica, Aucklandia lappa, Inula racemosa, and so on, where
it can be isolated at ease by means of different chromatographic techniques [108–111].
Three key reaction steps categorized by Marshall and coworkers are as follows: first,
the construction of the carboxylic scaffold by cationic olefin cyclization (212 to 213), sec-
ondly, modification of the carbon framework to afford 222, and lastly, formation of α-
methylene-γ-butyrolactone (222 to 184). The actual synthesis of Alantolactone (184) is
summarized in Scheme 47, commencing with unsaturated ketone 211 afforded from 4-
bromobutene in two steps [107]. Ketone 211 then was reacted with ethereal methylithium
to give alcohol 212, which was cyclized to generate formate 213 according to a procedure
previously developed by Johnson and co-workers for analogous compounds [112]. Alcohol
214 produced from saponification of the resulting formate 213 was oxidized with chromic
acid reagent giving octalone 215 [113]. Upon treatment of ethyl bromacetate to 215 via Stork
enamine procedure and saponification of the crude mixture, keto acid 216 was afforded
in 53% overall yield [107]. It should be noted that steric effects around C-9 rendered the
alkylation difficult and thus formed ∆7-isomer more predominantly than ∆7-isomer, which
eventually led to the formation of C-alkylation product 216 in high yield [114]. Keto acid
216 underwent esterification to furnish, after reduction with methanolic potassium boro-
hydride, unsaturated lactone 219. Photo-oxygenation of 219 as stated in the procedure by
Nickon and Bagli gave hydroperoxide 220 [115], which was directly reduced to alcohol 221
due to stability issue [107]. The key intermediate 222 was obtained by unsaturation of the
alcohol 221 upon treatment with thionyl chloride in pyridine according to the procedure
described by Benesova et al. [116]. Lactone 222 was converted to lactone ester 223 via
carbomethoxylation with sodium hydride in dimethyl carbonate. 223 was then reduced
without further purification to yield diol 224. Finally, diol 224 was subjected to oxidation
with manganese dioxide in benzene to afford racemic alantolactone (184). The stereoselec-
tive total synthesis of racemic alantolactone (184) elucidated by Marshall and co-workers
provided an approach to related sesquiterpene lactones [107].
Kaur and co-workers have recently reported a number of semi-synthetic derivatives
(225–228) of the natural product and their biological evaluation [117]. Alantolactone (184),
upon reaction with diazomethane, afforded pyrazoline derivative 228 as a major product
(Scheme 48). Alantolactone (184) underwent epoxidation reaction with trifluoroacetic acid
in dichloromethane as a solvent to generate compound 229 [118]. Moreover, alantolactone
(184), like other α-methylene-γ-lactone moiety containing sesquiterpene lactones, was read-
ily reacted with various amines to yield amine adduct 230 in a stereoselective manner [119].
Shul’ts et al. investigated the pharmacological properties caused by an arylidene fragment
in the lactone ring [120]. Thus, aromatic substituents at position C-13 was introduced via
Heck reaction with aryl iodides. Compound 231 having (E)-configuration was afforded by
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arylation with iodoarenes in the presence of Pd(OAc)2/(2-MeC6H4)3 and trimethylamine
in DMF. The configuration of the C(11)=C(13) double bond of 231 was determined by
analysis of 13C NMR spectrum.
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Scheme 48. Synthetic transformations of alantolatone (184). Reagents and conditions: (a) CHBr3, 
50% aq. KOH, TEBAC, 5 h; (b) NaBH4, MeOH, 25 min; (c) Mg, dry MeOH, 3 h; (d) TEA, diazome-
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2.2.5. Biological Activities of Deoxyelephantopin (185) 
Deoxyelephantophin (DET) (185) is the major sesquiterpene lactone component pre-
sent in extracts of medicinal herb Elephantopus scaber, which has long been used as a rem-
edy for various types of diseases such as hepatitis, arthritis, asthma, and cancer [121,122]. 
Recent studies showed that DET exhibits a broad spectrum of antitumor activities includ-
ing nasopharyngeal [123], cervical [124], colorectal [125], lung [126], skin [127], and par-
ticularly in breast cancer [128]. Characteristic structural feature of DET is a functionalized 
germacranolide skeleton, which is a 10-membered ring with a trans-fused α-methylene-
γ-lactone. It is widely accepted that an α, β-unsaturated ketones, and an α-methylene-γ-
lactone group of this natural product attribute to a variety of biological effects by acting 
as a Michael acceptor for nucleophilic amino residues like a cysteine [129]. 
Although inhibitory activities of DET (185) on NK-κB pathways and partial agonistic 
inhibition of PPARγ were previously described [130,131], covalent targets of DET (185) 
were not clearly assessed. Lagoutte et al. sought to find out direct cellular targets of DET 
(185) with the use of a proteome-wide identification technique. During the investigation, 
they were able to identify several cellular targets of DET (185) (RBP4, GSTA2, SLC26A3, 
LIPA, and ANXA1) and reported DET (185) as the first example of a small molecule that 
modulates a pharmacologically important nuclear receptor, PPARγ [132,133], activity by 
engaging a zinc finger through Michael addition [134]. 
In addition, Nakagawa-Goto et al. reported the design and synthesis of deoxy-
elephantophin derivatives (DETDs) and conducted a comprehensive structural-activity 
relationship study of DETDs on triple-negative breast cancer (TNBC) cell lines. TNBC ac-
counts for around 15% of breast cancers and notorious for having a poor prognosis 
[135,136]. TNBC, as its name implies, lacks conventional molecular targets usually found 
in breast cancers namely: estrogen receptor (ER), progesterone receptor (PR), and human 
epidermal growth receptor2 (HER2). This makes effective treatment for TNBC extremely 
challenging. Among all derivatives synthesized, DETD-35 (232) containing a naphthyl 
group attached to the ketone by a methylene linker showed the most potent activity and 
no toxicity towards normal cells in vitro (GI50 of DETD-35 (232) against MDA-MB-231, a 
TNBC cell line = 3.5 μM, Figure 11). Moreover, the effects of DET-35 (232) on inhibiting 
cell migration, invasion, and motility of MDA-MB-231 cells were shown to be better than 
that of the parental compound DET (185). Lastly, a combination of DETD-35 (232) with a 
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edy for various types of diseases such as hepatitis, arthritis, asthma, and cancer [121,122].
Recent studies showed that DET exhibits a broad spectrum of antitumor activities including
nasopharyngeal [123], cervical [124], colorectal [125], lung [126], skin [127], and particularly
in breast cancer [128]. Characteristic structural feature of DET is a functionalized germacra-
nolide skeleton, which is a 10-membered ring with a trans-fused α-methylene-γ-lactone.
It is widely accepted that an α, β-unsaturated ketones, and an α-methylene-γ-lactone group
of this natural product attribute to a variety of biological effects by acting as a Michael
acceptor for nucleophilic amino residues like a cysteine [129].
Although inhibitory activities of DET (185) on NK-κB pathways and partial agonistic
inhibition of PPARγ were previously described [130,131], covalent targets of DET (185)
were not clearly assessed. Lagoutte et al. sought to find out direct cellular targets of DET
(185) with the use of a proteome-wide identification technique. During the investigation,
they were able to identify several cellular targets of DET (185) (RBP4, GSTA2, SLC26A3,
LIPA, and ANXA1) and reported DET (185) as the first example of a small molecule that
modulates a pharmacologically important nuclear receptor, PPARγ [132,133], activity by
engaging a zinc finger through Michael addition [134].
In addition, Nakagawa-Goto et al. reported the design and synthesis of deoxyelephan-
tophin derivatives (DETDs) and conducted a comprehensive structural-activity relationship
study of DETDs on triple-negative breast cancer (TNBC) cell lines. TNBC accounts for
around 15% of breast cancers and notorious for having a poor prognosis [135,136]. TNBC,
as its name implies, lacks conventional molecular targets usually found in breast cancers
namely: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth
receptor2 (HER2). This makes effective treatment for TNBC extremely challenging. Among
all derivatives synthesized, DETD-35 (232) containing a naphthyl group attached to the
ketone by a methylene linker showed the most potent activity and no toxicity towards nor-
mal cells in vitro (GI50 of DETD-35 (232) against MDA-MB-231, a TNBC cell line = 3.5 µM,
Figure 11). Moreover, the effects of DET-35 (232) on inhibiting cell migration, invasion,
and motility of MDA-MB-231 cells were shown to be better than that of the parental com-
pound DET (185). Lastly, a combination of DETD-35 (232) with a cytotoxic drug, paclitaxel,
showed synergistic effects on MDA-MB-231 cells, suggesting that DETD-35 (232) could be
further developed as a potential compound to complement chemotherapeutic drugs used
for TNBC [137].
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Besides, in another study carried out by the group, it was demonstrated that DETD-
35 (232) also shows synergism with other BRAFV600E inhibitors, vemurafenib (PLX4032),
to overcome acquired vemurafenib resistant BRAFV600E mutant melanoma in a mouse
model [127]. These findings further reinforce the significance of DETD-35 (232) as a novel
chemical entity for anti-cancer drug discovery campaign.
2.2.6. Chemistry of Deoxyelephantopin (185)
Deoxyelephantopin has received much interest because of its impressive in vitro
and in vivo activities. However, total synthesis of deoxyelephantopin (185) has not been
reported up-to-date, probably for the same reason as in the case of alantolactone (184).
Lagoutte et al. profoundly explored the synthesis in regard to deoxyelephantopin (185)
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as part of their endeavor to develop synthetic methodologies to provide analogs of the
natural compound, including alkyne tagged probes to be used in target identification [134].
According to the retrosynthetic analysis provided by the group (Figure 12), deoxyelephan-
topin (185) and its analogs were envisioned to be obtained via Barbier-type allylation
of fragment 234 and bromolactone 235, followed by a late-stage ring-closing metathesis
(RCM) on substrate 233. Barbier-type allylation, which serves as the key reaction step in
the synthetic route, enables the diastereoselective coupling of the intermediate 235 with
diverse aldehydes [19].
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As expected, the zinc-mediated Barbier-type allylation of fragments 234 and 235 pro-
vided secondary alcohol 243 in moderate yield [138]. However, the resulting alcohol 243 
did not undergo RCM to produce the cyclized product (Scheme 50). Authors assumed 
that presence of free alcohol might interfere with the intermediate ruthenium carbene, 
hindering formation of the desired RCM product 244. Therefore, alcohol 243 was esteri-
fied to give methacrylate 233, which, however, also did not provide the product 246 upon 
submission to various RCM conditions [19]. RCM was not proceeded with the silyated 
compound 245 as well, suggesting the presence of free alcohol might not be responsible 
for this failure. 
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Scheme 49. (a) Synthesis of bromolactone 235; (b) synthesis of fragment 234 [19].
As expected, the zinc-mediated Barbier-type allylation of fragments 234 and 235
provided secondary alcohol 243 in moderate yield [138]. However, the resulting alcohol
243 did not undergo RCM to produce the cyclized product (Scheme 50). Authors assumed
that presence of free alcohol might interfere with the intermediate ruthenium carbene,
hindering formation of the desired RCM product 244. Therefore, alcohol 243 was esterified
to give methacrylate 233, which, however, also did not provide the product 246 upon
submission to various RCM conditions [19]. RCM was not proceeded with the silyated
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Formation of a medium-sized tri-substituted olefin under RCM conditions is known
to be particularly difficult [139,140]. Authors attempted to investigate whether the failure
resulted from the presence of the methyl group or the ring tension. For this purpose, RCM
precursor 248, which lacks a methyl group, was used in the reaction (Scheme 51). Upon
treatment with Grubbs I in refluxing dichloromethane, 248 was successfully converted
to the ring closed product as a single diastereomer, nordeoxyelephantophin 249. Lastly,
249 was treated with meta-chloroperbenzoic acid (mCPBA) to generate norelephantopin
250. Further investigation to cyclize the carbon skeleton of deoxyelephantopin is well
elaborated in the reference [19].
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Nakagawa-Goto et al. reported a number of semi-synthetic derivatives of the natural 
product and their biological assessment [137]. The synthesis commenced with hydrolysis 
of deoxyelephantopin (185) with NaOH followed by acidic treatment (Scheme 53). Ac-
cording to a previous report on cnicin [141], the group expected C-8 alcohol 263 to be 
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Sche e 51. Synthesis of nordeoxyelephantophin (249) and norelephantophin (250) by
Lagoutte et al. [19].
In addition, Lagoutte et al. synthesized deoxyelephantopin-related probes 254–256
and simplified analogs 258 and 260, which were utilized to indirectly demonstrate in-
teraction between deoxyelephantopin and PPARγ [134]. Although synthetic access to
deoxyelephantopin (185) could not be elucidated despite their efforts, preparation of
deoxyelephantopin-related analogs and probes, by means of a short and divergent synthetic
design, was comprehensively described during the journey towards deoxylelephantopin
(Scheme 52).
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The sesquiterpene lactone, costunolide (186), which belongs to a member of the ger-
macranolide subclass, was reported to be first isolated from roots of Saussrea lappa Clarke, 
also known as costus [142]. Costunolide (186) can be found in extracts of a number of 
medicinal plants including Vladimiria souliei Ling, Alucklandia lappa Decne, and Laurus no-
bilis L. as well [143]. Furthermore, costunolide (186) is served as a common biosynthetic 
precursor to three main types of sesquiterpene lactones such as germacranolide, eudes-
manolide, and guianolide [144,145]. 
Costunolide (186), like many other naturally occurring lactones, exhibits a variety of 
biological effects, including anti-cancer, anti-inflammation, anti-oxidant, anti-ulcer, and 
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on various tumor cells [153,154]. To date, researches indicate that costunolide (186) in-
duces apoptosis in three different apoptotic pathways, which eventually influences one 
another: (a) Mitochondria-mediated (intrinsic) pathway [153–155], (b) Death receptor-me-
diated pathway [156], and (c) Endoplasmic reticulum stress pathway [157,158]. 
According to studies conducted by Jeong et al., costunolide (186) reduced vascular 
endothelial growth factor (VEGF)-induced proliferation [159]. VEGF is an angiogenic mol-
ecule involved in formation of new blood vessels, which is particularly important for sur-
vival of cancer cells. Costunolide (186) showed inhibitory effects on VEGF-stimulated ne-
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2.2.7. Biological Activities of Costunolide (186)
The sesquiterpene lactone, cost nolide (186), which belongs to a member of the ger-
macranolide subclass, was reported to be first isolated from roots of Saussrea lappa Clarke,
Int. J. Mol. Sci. 2021, 22, 1052 34 of 67
also known as costus [142]. Costunolide (186) can be found in extracts of a number of
medicinal plants including Vladimiria souliei Ling, Alucklandia lappa Decne, and Laurus
nobilis L. as well [143]. Furthermore, costunolide (186) is served as a common biosyn-
thetic precursor to three main types of sesquiterpene lactones such as germacranolide,
eudesmanolide, and guianolide [144,145].
Costunolide (186), like many other naturally occurring lactones, exhibits a variety of
biological effects, including anti-cancer, anti-inflammation, anti-oxidant, anti-ulcer, and so
on [146–149]. Anti-cancer effects of costunolide (186) have been extensively explored in
recent researches [150–152]. Costunolide (186) is reported to modulate cyclin-dependent
kinases (CDKs) and block G2/M phase of the cell cycle to exert anti-proliferative effects on
various tumor cells [153,154]. To date, researches indicate that costunolide (186) induces
apoptosis in three different apoptotic pathways, which eventually influences one another:
(a) Mitochondria-mediated (intrinsic) pathway [153–155], (b) Death receptor-mediated
pathway [156], and (c) Endoplasmic reticulum stress pathway [157,158].
According to studies conducted by Jeong et al., costunolide (186) reduced vascular
endothelial growth factor (VEGF)-induced proliferation [159]. VEGF is an angiogenic
molecule involved in formation of new blood vessels, which is particularly important for
survival of cancer cells. Costunolide (186) showed inhibitory effects on VEGF-stimulated
neovascularization in mouse corneal mouse pocket analysis [159]. Moreover, it was re-
ported in another study that costunolide (186) was able to reduce VEGF receptor1 (VEGFR1)
and VEGFR2 expression at both mRNA and protein levels, suggesting the potential anti-
angiogenic activities of costunolide (186) [160].
Migration of cancer cells into surrounding tissues and distant sites in the body to
develop tumors in new locations is called metastasis, which is the leading reason for the
mortality of many patients with cancer [161]. Lymphatic metastasis, of other various forms
of cancer metastasis, is known to be an important determining factor in cancer staging and
therapy. Jeong et al. suggested, in part of their investigation, that costunolide (186) might
provide clinical benefits as an anti-lymphoproliferative agent during tumor metastasis,
based on the observed inhibitory activities of the compound on proliferation and capillary
formation of temperature-sensitive mouse lymphoid endothelial (TL-LE) cells [162].
In an effort to improve cytotoxic effects of costunolide (186) on cancer cells, Srivastava,
et al. synthesized a number of 13-amino costunolide derivatives by means of Michael-type
addition between costunolide (186) and various amines [163]. Among the derivatives,
3-methyl piperidine derivative (264) possessed 2-fold better cytotoxicity (GI50 = 3.3 µM)
than that of costunolide (186) (GI50 = 7.8 µM) on SW-620 colon cancer cells (Figure 13).
Two derivatives of hydroxyl piperidine series (structures not shown) also showed also in-
creased cytotoxicity against MIAPaCa2, K-562, and PA-1 cell lines. Moreover, it is notewor-
thy that the replacement at position-13 with an acyclic N,N-dimethyl group (265) increased
cytotoxicity in all cancer cell lines except for A-549 and SW-620. Authors suggested that
the amino substituents at position-13 of cosutnolide (186) might play an important role in
eliciting cytotoxicity [163].
More recent study on the structure and activity relationship of costunolide (186)
was conducted by Vadaparthi, et al. [164]. The group was able to synthesize a series of
analogs by utilizing Heck reaction conditions with various aryl iodides and cytotoxic
activities of the compounds were examined against a panel of human cancer cell lines,
including cervical cancer (HeLa), breast cancer (MCF-7), lung cancer (A-549), melanoma
(B-16), and prostate cancer (DU-145) cell lines in vitro. Amongst derivatives, compound
266c and 266j displayed potent activity against Hela, DU-145, and MCF-7 cell lines [164].
Further investigation to establish concrete effects brought by incorporating aromatic and
hetero-aromatic rings on costunolide (186) scaffold would be indispensable.
Taken all together, costunolide (186) is a potential anti-cancer agent with cytotoxic,
anti-angiogenic, and anti-lymphoproliferative activities. Therefore, structural modifications
of costunolide (186) might provide more opportunities in developing new natural lactone-
based cancer therapeutics.
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2.2.8. Chemistry of Costu olide (186)
The first total synthesis of (+)-costunolide (186) via the Cope rearrangement of synthetic
dehydrosaussurea lactone (267) was reported by Grieco et al. in 1976 (Scheme 55) [165].
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synthesis began with the keto-lactone 269, whic was obtained from santonin 268
in two steps (Scheme 56). Keto-lactone 269 was treated with tosylhydrazine to pr vide the
corresponding hydrazone, which was subsequently treated with lithium diisopropylamide
to afford olefin 270. The resulting olefin underwent ozonolysis followed by treatment with
sodium borohydride to yield diol 271. Authors expected bis-o-nitrophenyl selenide 272
would be directly obtained from the diol 271, which would, after oxidation, result in the
formation of saussurea lactone 273. However, this reaction with 271 only provided a side
product illustrated in ref. [165].
Gratifyingly, diol 271, upon treatment with o-nitrophenyl selenocyanate, tributylphos-
phine in tetrahydrofuran-pyridine (1:1), provided mono-selenide 274 exclusively (Scheme 57).
However, no bis-selenide could be isolated, in spite of their attempt to convert 274 to
bis-selenide 272 by previously described reaction condition. In two subsequent reactions,
saussurea lactone 275 was afforded from 274. Selenylation of the lactone 275 followed by
treatment with 30% hydrogen peroxide in tetrahydrofuran provided key intermediate de-
hydrosaussurea lactone 277, which, upon thermolysis, provided a 20% yield of costunolide
(186) [165].
The second synthesis of costunolide (186) was reported by Kitagawa et al. [166].
The synthesis also commenced with a readily available terpenoid, E,E-farnesol (278), which
was converted to ω-bromo-farnesal (279) in three steps (Scheme 58). The key reaction step
involved in the synthesis is the intramolecular C-C bond formation of ω-bromo-farnesal
(279) to generate a racemic germacrane-skeletone (280), which was mediated by a low
valent chromium reagent. Dihydrocostunolide (281) obtained in 2 steps from germacrane-
skeletone (280), was then treated with lithium diisopropylamide (LDA), diphenyl selenide,
and hydrogen peroxide to afford costunolide (186) as a racemic mixture.
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Next, the cyclization precursor 288 was obtained over 7 steps. In order to achieve
the intramolecular cyclization of 288, various bases were explored: NaHMDS, LiHMDS,
and KHMDS, among which 4 equivalent of KHMDS provided the cyclized product 289
with the best yield (84%) (Scheme 61) [97]. The sulfone group of 289 was removed with
treatment of Mg/MeOH to afford 290 in 73% yield, which was then treated with pyridinium
p-toleunesulfonate (PPTS) in MeOH to give the key intermediate 291 in 78% yield. Lastly,
oxidation of 291 with MnO2 in CH2Cl2 produced (+)-costunolide (186) in 82% yield.
Srivastava et al. synthesized and evaluated 13-amino costunolide derivatives. Simple
Michael-type reaction with secondary amines were used to synthesize the derivatives
(Scheme 62). The stereochemistry at position-11 has been assumed, based on the following
literature finding in the reference [168]. With 264 and 265 as the most potent compounds,
authors indicated that N,N-dimethyl substituation at position-13 of costunolide (186) plays
a significant role in improving the cytotoxicity of the parent compound (186) [163].
Int. J. Mol. Sci. 2021, 22, 1052 38 of 67




Scheme 59. Synthesis of fragments 283 and 285 by Yang et al. [97]. 
Since the aldol reaction between 283 and 285 unfortunately resulted in poor regiose-
lectivity, with expected 286a obtained as a minor product, an alternative approach was 
necessitated (Scheme 60). The approach selected by the authors presumably proceeded 
through a chelated transition state to generate 286a as the major product over 2 steps. 
 
Scheme 60. Synthesis of intermediate 286 [97]. 
Next, the cyclization precursor 288 was obtained over 7 steps. In order to achieve the 
intramolecular cyclization of 288, various bases were explored: NaHMDS, LiHMDS, and 
KHMDS, among which 4 equivalent of KHMDS provided the cyclized product 289 with 
the best yield (84%) (Scheme 61) [97]. The sulfone group of 289 was removed with treat-
ment of Mg/MeOH to afford 290 in 73% yield, which was then treated with pyridinium p-
toleunesulfonate (PPTS) in MeOH to give the key intermediate 291 in 78% yield. Lastly, 
oxidation of 291 with MnO2 in CH2Cl2 produced (+)-costunolide (186) in 82% yield. 
 
Scheme 61. Synthesis of (+)-costunolide (186) from the key intermediate 291. Reagents and condi-
tions: (a) KHMDS, THF, 0 °C, 25 h, 85%; (b) Mg, MeOH, rt, 16 h, 74%; (c) PPTS, MeOH, rt, 20 min, 
78%; (d) MnO2, CH2Cl2, rt, 48 h, 82% [97]. 
c e e 61. t li e (186) fro the key intermediate 291. Reagents and condi-
ti s: ◦ , ; ) , e , rt, 16 h, 74 ; (c) PPTS, MeOH, rt, 20 min,
78 ; (d) n 2, 2 l2, rt, 48 h, 82 [97].
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 40 of 69 
 
 
Srivastava et al. synthesized and evaluated 13-amino costunolide derivatives. Simple 
Michael-type reaction with secondary amines were used to synthesize the derivatives 
(Scheme 62). The stereochemistry at position-11 has been assumed, based on the following 
literature finding in the refere ce [168]. With 264 and 265 as the most potent compou s, 
authors indicated that N,N-dimethyl substituation at position-13 of costunolide (186) 
plays a significant role in improving the cytotoxicity of the parent compound (186) [163]. 
 
Scheme 62. Synthesis of 13-amino costunolide derivatives 264 and 265 [163]. 
Another synthesis of costunolide (186) derivatives was reported by Vadaparthi et al. 
[164]. The α-methylene-γ-lactone moiety was arylated by means of the Pd (II)-catalyzed 
Heck coupling reaction. In this study, costunolide (186) was coupled with various aryl 
iodides under standard Heck reaction condition (Scheme 63). The reaction seamlessly pro-
vided the E-olefin products (266a–266l), exclusively. The C11-C13 olefin was determined 
to be the E-configuration based on the observed diagnostic vinyl proton at C-13, with a 
range of 7.57–7.97 ppm [164]. Moreover, no structural reorganization or decomposition 
occurred during the reaction process [164]. Among the derivatives, 266c, 266d, and 266j 
were highly active against Hela (cervical cancer), DU-145 (prostate cancer), and MCF-7 
(breast cancer) cell lines. 
 
Scheme 63. Synthesis of arylated costunolide derivatives (266a–266l) [164]. 
Overall, those fruitful researches carried out on the chemistry of costunolide (186) 
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2.2.9. Biological Activities of Antrocin (187) 
Antrocin (187) is a sesquiterpene lactone mainly present in the extracts of Antrodia 
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other synthesis of costunolide (186) derivatives was reported by Vadap rthi et al. [164].
The α-methylene-γ-lactone moiety was arylated by means of the Pd (II)-catalyzed Heck
coupling reaction. In this study, costunolide (186) was coupled with various aryl iodides
under standard Heck reaction condition (Scheme 63). The reaction seamlessly provided
the E-olefin products (266a–266l), exclusively. The C11-C13 olefin was determined to be
the E-configuration based on the observed diagnostic vinyl proton at C-13, with a range
of 7.57–7.97 ppm [164]. Moreover, no structural reorganization or decomposition occurred
during the reaction process [164]. Among the derivatives, 266c, 266d, and 266j were highly
active against Hela (cervical cancer), DU-145 (prostate cancer), and MCF-7 (breast cancer) cell
lines.
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Overall, those fruitful researches carried out on the chemistry of costunolide (186)
provided new insight with regard to the efficient synthesis and structural modification of
the natural lactone (186).
2.2.9. Biological Activities of Antrocin (187)
Antrocin (187) is a sesquiterpene lactone mainly present in the extracts of Antrodia
camhorata (also known as Antrodia cinnamomea), a medical mushroom widely used as a
dietary supplement for cancer prevention and hepatoprevention in Asia [169]. Antrodia
camhorata has been traditionally used as a remedy for drug intoxication, abdominal pain,
food poisoning, and cancer [170]. Currently, antrocin (187) is identified as the compound
that contributes to the pharmacological efficacy of Antrodia camhorata [169]. Rao et al.
explored antrocin (187) and its biological mode of action [171]. During the evaluation of
antrocin (187) on cell proliferation, antrocin exhibited the most potent inhibitory activity
against breast cancer line MDA-MB-231 cells with a GI50 value of 0.6 µM [171]. Moreover,
authors insisted antropin (187) might be a novel molecule with efficacy as dual Akt/mTOR
inhibitor, based on their observation that the natural lactone inhibits cancer cell prolifer-
ation by promoting apoptosis through down-regulation of AKt/mTOR/GSK-3β/NF-κB
signaling pathways [171].
The group subsequently sought to investigate the capability of antrocin (187) to inacti-
vate other survival signaling pathways [172]. In this study, the effect of antrocin (187) on a
panel of non-small cell lung cancer (NSCLC) cells was examined. H1975 and H441 being
two representative cell lines exhibited high sensitivity to antrocin (187) (36–78% inhibition,
49–85% inhibition, respectively) [172]. Antrocin (187) also inactivated STAT3 and pre-
vented its nuclear localization in H441 cells, indicating its action as a JAK/STAT3 signaling
inhibitor. Furthermore, antrocin (187) suppressed tumorigenesis in lung cancer mouse
xenograft in vivo and enhanced tumor inhibitory response upon combinatorial treatment
of antrocin (187) and JAK2 inhibitor [172].
More recently, Chen et al. reported antrocin (187) as an anti-TNBC agent without
apparent systematic toxicity, based on their preliminary toxicological evaluation performed
with antrocin (187) in a 28-day rat study (at 37.5 mg/kg) [173]. In addition, another study
demonstrated that antrocin (187) effectively enhances sensitization radio-resistant prostate
cancer cells to radiation [174]. Given together, antrocin (187) has the capability to be a
therapeutic and sensitizing agent for various cancers.
2.2.10. Chemistry of Antrocin (187)
A concise and asymmetric synthesis of antrocin (187) has been reported by Li et al. [175].
The synthesis began with the naturally abundant carnosic acid as a chiral pool. After subjec-
tion of carnosic acid (292) to ozonolysis, followed by reduction with NaBH4, optically pure
lactone 293 was afforded in 58% yield (Scheme 64). Lactone 293 was directly converted to
hydroxyl lactone 295 in two steps, which was subsequently treated with I2 in the presence
of PPh3 and imidazole to produce iodide 296. Lastly, treatment of 296 with DBU afforded
antrocin (187) in 50%. The asymmetric synthesis of antrocin (187) as achieved by the group
with a 16.1% overall yield in five steps [175]
Recently, the total synthesis of natural (−)-antrocin (187) and its enantiomer has been
reported [176]. Despite remarkable antitumor activities, the difficulties to prepare (−)-
antrocin (187) triggered researchers to find a synthetic alternative. Since there was no
available simple and inexpensive synthetic method for (−)-antrocin (187) until recently,
authors focused on developing a synthetic approach using inexpensive, readily available
starting material 6-methoxy-2-tetralone 297 and simple chemical operations.
From commercially available starting material 297, trans-cyano bicyclic ketone (±)-298
was obtained as a major product over 4 steps (Scheme 65). Resolution of the compound
(±)-298 was performed by utilizing (+)-dimethyl tartrate (DMT), which yielded separable
1:1 diasteromic mixture of ketal (−)-299 and (+)-300.
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( ). t c itions: (a) O3,
CH2Cl2/MeOH (3/1), 78 ◦C, 1.5 h, then NaBH4 (6.0 equiv.), 78 ◦C to r , 1 h (58%); (b Ph3 (1.3 equiv),
I2 (1.5 equiv), imidazole (1.5 equiv), THF, 0 ◦C to rt, 1 h (99%); and (c) DBU (10.0 equiv), toluene,
80 ◦C, overnight (50%) [175].
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2.2.11. Biological Activities of EM23 (188) and Brevilin A (189) 
EM23 (188) is a natural sesquiterpene lactone derived from Elephantopus mollis. Shao 
et al. investigated anticancer effects of EM23 (188). EM23 (188) exhibited growth inhibitory 
activity against various cancer cell lines, including A549 (lung cancer), MCF-7 (breast can-
cer), TE-1, EC109, and EC9706 (esophageal cancer), CaSki and SiHa (cervical cancer), and 
HL-60 and K562 (leukemia) [179]. EM23 (188) showed the most potent anti-proliferative 
activity against CaSki and SiHa with a GI50 value of 5.8 and 6.6 μM, respectively. Further-
more, the authors proposed the mechanism of EM23-induced apoptosis. Thioredoxin re-
ductase (TrxR) catalyzes the reduction of thioredoxin (Trx), which participates in various 
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Ketal (−)-299 was selected for further reaction to complete the synthesis of antrocin
(187). Keto aldehyde (+)-301 was prepared from (−)-299 over 3 steps (Scheme 66). Next,
α-hydroxymethylation of (+)-301 by reacting with lithium enolate with gaseous formalde-
hyde in THF yielded a single lactol (+)-302. The authors proposed that this reaction is
controlled kinetically [176]. Lactol (302) was then oxidized with silica-supported pyri-
dinium chlorochromate (PCC) to give lactone (−)-303. Authors attempted both standard
and modified Wittig olefination (Ph3PCH2 and THF, 0 ◦C and Ph3PCH2, toluene, and
t-BuOH, rt) [177], which ended up with a poor conversion rate (30–30%). Gratifyingly,
another attempt with non-basic Lombardo’s reagent (Zn, TiCl4, CH2Br2) led to successful
olefination of ketone (−)-303 to antrocin (187) in excellent yield (98%) [178].
2.2.11. Biological Activities of EM23 (188) and Brevilin A (189)
EM23 (188) is a natural sesquiterpene lactone derived from Elephantopus mollis. Shao et al.
investigated anticancer effects of EM23 (188). EM23 (188) exhibited growth inhibitory activity
against various cancer cell lines, including A549 (lung cancer), MCF-7 (breast cancer), TE-1,
EC109, and EC9706 (esophageal cancer), CaSki and SiHa (cervical cancer), and HL-60 and
K562 (leukemia) [179]. EM23 (188) showed the most potent anti-proliferative activity against
CaSki and SiHa with a GI50 value of 5.8 and 6.6 µM, respectively. Furthermore, the authors
proposed the mechanism of EM23-induced apoptosis. Thioredoxin reductase (TrxR) catalyzes
the reduction of thioredoxin (Trx), which participates in various cellular processes [180].
Overexpression of Trx/TrxR is found to be related in the development and progression of
cancer [181,182]. EM23 (188) inhibits the expression levels of TrX/TrxR to facilitate ROS
accumulation, which results in the dissociation of ASK1 from complex with Trx and activation
of downstream JNK signaling pathway [179]. Taken together, EM23 (188) can be potentially
applied as an anticancer agent for human cervical cancer by a structural modification to
achieve further enhancement in potency.
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HL-60 and K562 (leukemia) [179]. EM23 (188) showed the most potent anti-proliferative 
activity against CaSki and SiHa with a GI50 value of 5.8 and 6.6 μM, respectively. Further-
more, the authors proposed the mechanism of EM23-induced apoptosis. Thioredoxin re-
ductase (TrxR) catalyzes the reduction of thioredoxin (Trx), which participates in various 
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Brelivin A (189) is a bioactive component mainly present in Centipeda minima (L.)
A [183]. It has been reported to display anticancer activities. In acute promyelocytic
leukemia HL-60 cells, Brevilin A (189) induced apoptosis through a mitochondrial/caspase
pathway [184]. Moreover, treatment of Brevilin A (189) reversed vincristine resistance in
multidrug-resistant colorectal cancer cell line HCT-8/VCR by inhibiting the intracellular
accumulation of YB-1 and down-regulating MDR1 expression, two important factors closely
related to multidrug resistance. This suggests Brevilin A (189) as a potential anticancer
drug adjuvant to reverse drug resistance in chemotherapy [185]. In addition, Chen et al.
reported that Brevilin A (189) acts as a STAT3 signaling inhibitor [186]. Persistent STAT3
activity is associated with cancer progression, most of which show aberration of JAKs,
Src, or other receptor tyrosine kinases. Brevilin A (189) inhibited both constitutively
activated-STAT3 driven DU145 (prostate cancer) and MDA-MB-468 (breast cancer) cell
lines [186]. It is also noteworthy that Brevilin A (189) specifically inhibits JAKs without
other signaling proteins such as p65, AKT, GSK-3β, and Src. A number of Brevilin A (189)
derivatives were synthesized and their anticancer potential was evaluated in a structure-
activity relationships study conducted by Lee et al. [187]. During the course of the study,
it was found out that the alkene or carbonyl of the enone moiety is crucial in achieving
cytotoxicity. Most notably, introducing different substituents to the α-position of the
γ-lactone ring exhibited a significantly increased cytotoxicity in the tested cancer cell
lines. In the MDA-MB-231 and A549 cell lines, BA-9 (304) and BA-10 (305) displayed a
GI50 value of 4.647 µM and 6.385 µM against MDA-MB-231 and 6.239 µM and 6.392 µM
against A549, respectively (Figure 14). These values exhibited by the derivatives are
roughly two-fold greater than that of the parent compound Brevilin A (189) (GI50 in
MDA-MB-231 = 7.03 µM, A549 = 10.09 µM), indicating potential of BA-9 (304) and BA-10
(305) as promising candidates for further development as cancer therapeutics [187].
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2.2.12. Chemistry of EM23 (188) and Brevilin A (189) 
To the best of our knowledge, there are no reports elucidating total synthesis of EM23 
(188) and Brevilin A (189) up-to-date. Semi-synthetic derivatives of Brevilin A (189) were 
prepared by Lee et al. [187]. Key intermediate BA-8 (306) was obtained via aldol reaction 
between Brevilin A (189) and paraformaldehyde in the presence of sodium carbonate 
(Scheme 67). Subsequently, C11-hydroxylmethyl of BA-8 (306) was actylated with p-nitro-
bezoyl chloride and methacrylic anhydride to yield BA-9 (304) and BA-10 (305), respec-
tively. 
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Diacylglycerol lactones (DAGLs) are synthetic lactones derived from syn-1,2-diacyl-
glycerol (DAG), which is a key lipid second messenger that binds to the C1 domain in 
many regulatory proteins [188]. This lipophilic second messenger plays a key role in sig-
nal transduction pathways [14]. DAG especially acts as an endogenous activator by bind-
ing to the C1 domain of protein kinase C (PKC). Upon binding, it allosterically activates 
the enzyme in the presence of phospholipid [189]. The PKC family can be classified into 
three isoenzyme groups: conventional (α, βI, βII, and γ), novel (δ, ε, η, and θ), and atypical 
(ζ and ι/λ) [189]. Only conventional and novel isoenzymes contain C1 regions. PKC 
isoforms constitute the most prominent family of signaling proteins that control cellular 
functions such as proliferation, survival, motility, tumorigenesis, and metastasis [189]. 
Therefore, their significance in pathogenesis has driven much interest in the C1 domain 
as a therapeutic target [189]. Furthermore, implication of PKCs in a range of cancer in 
different organs increases its potential as a therapeutic target [190–192], which eventually 
led to a thorough investigation on DAG-based small molecule PKC modulators. 
2.3.1. Biological Activities of Diacylglycerol Lactones 
DAG binds to the C1 domain of PKC isoenzymes containing a cysteine-rich, zinc fin-
ger-like motif [193]. However, competence between DAG and phorbol esters might occur 
because they share the same binding site. The binding affinity of phorbol esters is higher 
than that of DAG by at least 3 orders of magnitude [14]. Upon binding of the phorbol 
esters, PKC activation bypasses the normal physiological signal-mediated mechanism, in 
which responses irrelevant to DAG could be activated [194]. To overcome this challenge, 
the group of Blumberg and Marquez designed a series of structurally simple cyclic DAG-
based molecules to surpass the binding affinity of DAG to PKC [14]. They reasoned that 
the low binding affinity of DAG is caused by the flexible nature of the glycerol backbone 
and, therefore, giving it an entropy penalty by restricting the conformation would increase 
the binding affinity towards PKC. With this rationale, Kang et al. obtained 4,4-disubsti-
tuted-γ-butyrolactone as an ideal glycerol template [189]. Their extensive SAR studies 
based on pharmacophore-guided and receptor guided approaches provided notable find-
ings to increase binding affinity from DAG (307, Ki ≈ 1 μM) through cyclization to the 
structurally constrained 5-tetradecanoyl DAG-lactone (308, Ki ≈ 138 nM), shifting of the 
hydrophobic alkyl chain from the 5-acyl to the 3-alkylidene position (309, Ki ≈ 30 nM), and 
incorporating highly branched alkyl chain (310, Ki ≈ 2.9 nM) (Figure 15). 
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2.3.1. Biological Activities of Diacylglycerol Lactones
DAG binds to the C1 domain of PKC isoenzymes containing a cysteine-rich, zinc
finger-like motif [193]. However, competence between DAG and phorbol esters might
occur because they share the same binding site. The binding affinity of phorbol esters
is higher than that of DAG by at least 3 orders of magnitude [14]. Upon binding of
the phorbol esters, PKC activation bypasses the normal physiological signal-mediated
mechanism, in which responses irrelevant to DAG could be activated [194]. To overcome
this challenge, the group of Blumberg and Marquez designed a series of structurally simple
cyclic DAG-based molecules to surpass the binding affinity of DAG to PKC [14]. They
reasoned that the low binding affinity of DAG is caused by the flexible nature of the glycerol
backbone and, therefore, giving it an entropy penalty by restricting the conformation would
increase the binding affinity towards PKC. With this rationale, Kang et al. obtained 4,4-
disubstituted-γ-butyrolactone as an ideal glycerol template [189]. Their extensive SAR
studies based on pharmacophore-guided and receptor guided approaches provided notable
findings to increase binding affinity from DAG (307, Ki ≈ 1 µM) through cyclization to
the structurally constrained 5-tetradecanoyl DAG-lactone (308, Ki ≈ 138 nM), shifting of
Int. J. Mol. Sci. 2021, 22, 1052 43 of 67
the hydrophobic alkyl chain from the 5-acyl to the 3-alkylidene position (309, Ki ≈ 30 nM),
and incorporating highly branched alkyl chain (310, Ki ≈ 2.9 nM) (Figure 15).
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remaining 5-acyl group would achieve further enhancement in binding activity [189]. To 
this end, macrocyclization strategy to link the two terminal alkyl ends of the 5-acyl and 3-
alkylidene groups was used. They expected that this strategy would allow the ester to 
adopt the preferred S-trans configuration for ring sizes greater than ten, as well as render-
ing the physicochemical properties of the ligand suitable as drug candidates [189]. Among 
synthesized macrocyclic DAG-bis-lactones evaluated, compound 311 exhibited in Ki value 
of 6.07 nM against PKCα (Figure 16). In addition, the molecular docking study of 311 with 
PKCα suggests that the macrolactone 311 exclusively binds in the sn-1 binding mode to 
the C1b domain of the protein [189]. 
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Kang et al. synthesized and investigated a series of DAG-lactones with polar 3-alkyli-
dene substituents as PKCα and antitumor agents (Figure 17). The structure-activity rela-
tionships revealed that compounds 312, 313, and 314 with an ether side chain have high 
binding affinities (Ki = 3–5 nM) and excellent antitumor effects on colon cancer (Colo205, 
GI50 = 0.120–0.260 μg/mL) and leukemia cancer (K562, GI50 = 0.140–0.200 μg/mL) cell lines 
[195]. 
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Figure 6. Structure of acrocyclic -bis-lactones 311 [189].
Kang et al. synthesized and investigated a series of DAG-lactones with polar 3-
alkylidene substituents as PKCα and antitumor agents (Figure 17). The structure-activity
relationships revealed that compounds 312, 313, and 314 with an ether side chain have high
binding affinities (Ki = 3–5 nM) and excellent antitumor effects on colon cancer (Colo205,
GI50 = 0.120–0.260 µg/mL) and leukemia cancer (K562, GI50 = 0.140–0.200 µg/mL) cell
lines [195].
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with an E-conformation, as a selective ligand for PKCε (Ki of PKCα = 46 nM, Ki of PKCε = 
1.43 nM). Moreover, it should be noted that the selectivity was further enhanced in the 
nuclear membrane conditions, indicating strengthened interactions between the DAG-lac-
tone side chain and the protein-membrane interface [198]. With the help of chemically 
modified DAG-lactone, AJH-836 (315), additional efforts were made to highlight the im-
portance of PKCs in the transcriptional gene regulation in lung cancer cells [199]. Authors 
have added that the discovery of selective C1 domain ligands may lead to promising ther-
apeutic leads and pharmacological tools for identifying pathophysiological mechanism of 
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2.3.2. Chemistry of Diacylglycerol Lactones 
Synthesis of DAG-bis-macrolactone commenced with condensation reaction of γ-lac-
tone with aldehydes 317–320 to afford β-hydroxylactones, which were converted into 3-
alkylidene γ-lactone (321–327) as mixtures of E/Z isomers (Scheme 68). With the key in-
termediate 328–334 obtained over 3 steps, macrolactonization was utilized according to 
Keck and Boden’s method to yield 13, 17, 21, and 25-membered macrolactones (335–341), 
respectively [200]. Lastly, benzyl group was removed to provide the target macrolactones 
(311, 342–347) [189]. 
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2.3.2. Chemistry of Diacylglycerol Lactones
Synthesis of DAG-bis-macrolactone commenced with condensation reaction of γ-
lactone with aldehydes 317–320 to afford β-hydroxylactones, which were converted into
3-alkylidene γ-lactone (321–327) as mixtures of E/Z isomers (Scheme 68). With the key
intermediate 328–334 obtained over 3 steps, macrolactonization was utilized according to
Keck and Boden’s method to yield 13, 17, 21, and 25-membered macrolactones (335–341),
respectively [200]. Lastly, benzyl group was removed to provide the target macrolactones
(311, 342–347) [189].
Due to high lipophilicity of synthesized DAGLs, it was attempted to reduce the
lipophilicity by incorporating more polar side substituents in the 3-alkylidene chain. DAG-
lactones with polar 3-alkylidene chains were synthesized by alkylation of the protected
5,5-disubstituted γ-lactone with various polar side chains (Scheme 69) [195].
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AJH-836 (315), a PKCε selective DAG-lactone, was synthesized by Ann et al. [198]. 
The synthesis started with p-methoxyphenyl (PMP) and benzyl (Bn) protected racemic 
lactone (Scheme 70). Aldehyde 368 was reacted with the 367 to form olefin 369 via aldol 
condensation. After removal of PMP protection, the intermediate 370 was reacted with 
acyl chloride 371, followed by benzyl deprotection to afford the target molecule 315. 
. t sis of -bis- acrolactones [189]. Reagents and conditions: (a) (i) LiHMDS,
, ◦C; ( i) RC (13–16); (b) (i) sCl, Et3, CH2Cl2; (ii) DBU, 45–52% in 2 steps; (c) DMAP,
l, , 2Cl2, 60–70%; (d) BCl3, CH2Cl2, 80–92%.




Scheme 68. Synthesis of DAG-bis-macrolactones [189]. Reagents and conditions: (a) (i) LiHMDS, 
THF, −78 °C; (ii) RCHO (13–16); (b) (i) MsCl, NEt3, CH2Cl2; (ii) DBU, 45–52% in 2 steps; (c) DMAP, 
DMAP/HCl, DCC, CH2Cl2, 60–70%; (d) BCl3, CH2Cl2, 80–92%. 
Due to high lipophilicity of synthesized DAGLs, it was attempted to reduce the lip-
op ilicity by incorp rating more polar side substituents in the 3-alkylidene chain. DAG-
lactones with polar 3-alkylidene chains were synthesized by alkylation of the protected 
5,5-disubstituted γ-lactone with various polar side chains (Scheme 69) [195]. 
 
Scheme 69. Synthesis of hydroxyl and ether DAG-lactone analogs [195]. Reagents and conditions: 
(a) CAN, CH3CN–H2O, 0 °C; (b) (CH3)3CCOCl, Et3N, DMAP, CH2Cl2; (c) LiHMDS, CH3(CH2)12CHO 
for 350–351, RO(CH2)nCHO for 352–362, TrO(CH2)nCHO for 363–366, THF, −78 °C; (d) (i) MsCl, 
NEt3, CH2Cl2, (ii) DBU; (e) BCl3, CH2Cl2, −78 °C; (f) CF3CO2H, CH2Cl2, 0 °C. 
AJH-836 (315), a PKCε selective DAG-lactone, was synthesized by An  et al. [198].
The synthesis started with p-methoxyphenyl (P P) and benzyl (Bn) protected racemic 
lactone (Scheme 70). Aldehyde 368 was reacted with the 367 to form olefin 369 via aldol 
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2.4. Diterpene Lactones
Diterpenes are classes of natural products mostly originated from microbes or sec-
ondary metabolites of fungal sources. Diterpenes can be further classified into subdivisions
according to its structural feature (bicyclic, tricyclic, and tetracyclic diterpenes). This class
of compounds attracted researchers due to their potential biological activities including
anti-cancer, anti-oxidant, and anti-inflammatory effects [201,202].
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2.4.1. Biological Activities of Andrographolide (373)
Andrographolide (373) is a simple bicyclic labdane diterpene lactone belonging to
the isoprenoid family of natural products and is a well-known medicinal plant, which has
been widely used in Asia [203]. The lactone is isolated from the stem and leaves of Andro-
graphis paniculata (Burm.f.) Nees, also known as King of Bitters. [204]. The characteristic
structural features of andrographolide (373) include: α,β-unsaturated γ-butyrolactone ring,
three hydroxy groups (at C-3, C-14, and C-19), and two olefin bonds (∆8(17) and ∆12(13)).
Biological responses elicited by andrographolide (373) is mainly due to its ability to form
H-bonds with biological substrates by utilizing the hydroxyl group [205]. Andrographolide
(373) having potent cytotoxic effects against various cancer cells, it has been reported that
andrographolide (373) exerts the anti-cancer effects by modulating several cancer-related
pathways and proteins including JNK-signaling pathway, NF-κB and PI3K signaling path-
way, cyclins and cyclin-dependent kinases (CDKs), metalloproteinases (MMPs) and tumor
suppressor proteins (p53 and p21) [206].
Dai et al. demonstrated that andrographolide (373) prevents proliferation of human
gastric cancer cell line SGC-7901 by blocking cell cycle progression, promoting intrinsic
apoptosis, and/or repressing invasive activity [207]. Upon increasing concentrations of
andrographolide (373) (10, 20, and 40 µg/mL), cell-cycle inhibitory proteins (cyclin B1
and CDC2) and proapoptotic protein (Bax) were upregulated and antiapoptotic protein
(Bcl-2) was downregulated [207]. 19-triisopropyl andrographanolide (374), an analogue
of androgrphanolide (373), showed potent cytotoxic activity against gastric cancer cell
lines with a GI50 value of 6.3 µM and 1.6 µM for MKN-45 and AGS cell lines, respectively
(Figure 19). On the other hand, the parent andrographanolide (373) is show to be less
potent than the analog (374) with the GI50 valu s of >50 µM in MKN-45 and 11.3 µM in
AGS cell lines [208].
Andrographanolide (373) is also found to suppress tumor proliferation in prostate
cancer cells by modulating proimflammatory cytokines (interleukin (IL)-6) and chemokines
(CXCl11, CXCR3, and CXCR7) [209]. Moreover, administr ti n of andrograph nolide (373)
to DU145 (prostate cancer cell)-xenografted mice delayed tumor growth without obviou
toxicity [210]. SRJ23 ( 75), another andr graphanolide (373) analog, was synthesized to
improve the anti umor activity of the parent compound (373) against prostat cancer cell
lines (Figure 19). SRJ23 (375) selectively inhibited a prostate cancer cell (PCa) with a 50-
fold improved GI50 (0.4 µM) than that of the parent compound andrographanolide (373)
(GI50 = 19.95 µM) [211].
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to epoxide 378 in 79% yield over 5 steps (Scheme 71). For the efficient preparation of the 
key precursor 381, authors optimized the protocol based on their previous protocol, which 
includes 3 reaction steps [219]. Cyclopropyl ketone (378) underwent chemoselective 1,2-
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the resulting crude intermediate 380 was briefly treated with K2CO3 in methanol to give 
Colorectal cancer is a frequently diagnosed solid tumor. The main issue in this can-
cer is the high recurrence rate caused by acquired resistance to chemotherapies such as
5-fluorouracil (5-FU) and cisplatin [212,213]. In a study conducted by Wang et al. [212], an-
drographanolide (373), when treated to 5-FU-resistant colorectal cancer cell line (HCT116/5-
FUR), synergistically enhanced 5-FU-induced apoptosis. This suggests that andrographano-
lide (373) could reverse chemotherapy resistance and act as a sensitizing agent in colorectal
cancer Moreover, the clinical relevance of andrographanolide (373) in combination with
capecitabine is being investigated, which initiated a clinical trial in 2014 [214].
Another type of cancer highly related to poor prognosis and high recurrence rate is
non-small-cell lung cancer (NSCLC). Andrographanolide (373) showed synergistic antitu-
mor activity with chemotherapeutic agents cisplatin and paclitaxel, although the molecular
mechanism behind this synergism is still unclear [215,216]. Lim et al. reported an an-
drographanolide (373) analog, 3,14,19-tripropionylandrographolide (SRS06, 376), which
shows a distinct inhibitory activity against A549 NSCLC cell line. SRS06 (376) was able
to suppress cancer cell proliferation by downregulating the levels of NF-κB protein and
inhibiting p65 DNA binding activity at a concentration of 5 µM [217].
Despite various antitumor activities of andrographanolide (373), poor solubility and
relatively low potency still remained to be the main hurdles for further advancement
into clinical development. To overcome this challenge, more efforts in modification and
optimization of the chemical structures would be needed.
2.4.2. Chemistry of Andrographolide (373)
Gao et al. reported the first total synthesis of (−)-andrographolide (373) via biomimetic
cyclization approach, in which an epoxy homoiodo allylsilane precursor (381) was uti-
lized [218]. The synthesis commenced with geraniol 377, which was readily converted
to epoxide 378 in 79% yield over 5 steps (Scheme 71). For the efficient preparation of the
key precursor 381, authors optimized the protocol based on their previous protocol, which
includes 3 reaction steps [219]. Cyclopropyl ketone (378) underwent chemoselective 1,2-
addition with (phenyldimethylsilyl)methylcerium chloride to afford cyclopropyl carbinol
(379), which, upon exposed to MgI2, provided intermediate 380 as a crude mixture. Next,
the resulting crude intermediate 380 was briefly treated with K2CO3 in methanol to give
the key intermediate 381. Moreover, the authors found out that reaction temperature is
critical for Julia-type cyclopropane ring-opening of 379 [218].
The key reaction step utilized in this study is the biomimetic cation-olefin annula-
tion of epoxy homoiodo allylsilane precursor 381 to form bicyclic iodide 382 (Scheme 72).
By using the optimized cyclization condition (SnCl4 in CH2Cl2 at −40 ◦C), bicyclic iodide
382 was furnished as a mixture of C9 epimers (α/β 0.7:1). Subsequently, bicyclic iodide
382 was converted to bicyclic aldehyde 383 over 4 steps, which underwent aldol conden-
sation with the corresponding lithium enolate of (S)-(−)-β-hydroxy butyrolactone (384)
to give dihydroxy lactone 385 as a mixture of C-12 epimers. Compound 385 was then
selectively O-silyated via the mesylate intermediate to provide E-configurated lactone 386
Int. J. Mol. Sci. 2021, 22, 1052 48 of 67
in a regio- and stereoselective manner [218]. Lastly, desilylation and acetonide cleavage
of 386 provided (−)-andrographolide (373), which was spectroscopically identical to the
natural andrographolide [220].
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71. Synthesis of key intermediate 381 [218]. Reagents and conditions: (a). (i) PhMe2SiCH2MgCl,
CeCl3, THF, 0 ◦C–23 ◦C; (ii) 2.5 equiv MgI2·(OEt2)n (0.25 M in Et2 /PhH (1:1)), PhH, 50 ◦C, 15 min;
(iii) K2CO3, MeOH, 23 ◦C, 65%.
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72. Synthesi of andrographolide (373). Reagents a d co iti s: (a) 2.0 equiv SnCl4, CH2 l2
−40 ◦C, ca. 1 min.; (b) 1.6 equiv (S)-(−)-β-hydroxy-γ-buty lactone, 3.2 equiv LDA, THF/HMP
(4:1), −78 ◦C–30 ◦C, 64% (80% brsm); (c) TBSCl, imidazole, DMF, 23 ◦C, 76%; (d) MsCl, Et3N, CH2Cl2,
−78 ◦C–0 ◦C, 1 h; then iPr2NEt, CH2Cl2, 23 ◦C, 55%; (e) TBAF, THF, 23 ◦C, 57%; (f) HOAc/H2O (7:3),
23 ◦C, 89% [218].
A more concise and convergent enantioselective total synthesis of andrographolide
was recently reported by Yang et al. [221]. Key transformations utilized in the synthesis
include: (1) formation of quaternary C4 stereocenter via iridium-catalyzed carbonyl re-
ductive coupling, (2) establishment of the trans-decaline skeleton via diastereoselective
alkene reduction, and (3) installation of the α-alkylidene-β-hydroxy-γ-butyrolactone via
carbonylative lactonizaition. The synthesis began with preparation of acetonide 389, which
was achieved via a 6-step reaction (Scheme 73). The authors predicted that 389 would
undergo cycloaddition diastereoselectively from the convex face of the bicycle. As expected,
cycloadduct 390 was obtained as a single stereoisomer from Diels–Alder cycloaddition
of 389 with dimethylacetylene dicarboxylate (DMAD) [221]. For the construction of the
Int. J. Mol. Sci. 2021, 22, 1052 49 of 67
trans-decalin ring, manganese-catalyzed hydrogen atom transfer (HAT) was chosen be-
cause it enables diastereselective hydrogenation of the targeted alkene [222]. However,
HAT reduction of cycloadduct 390 exclusively provided the cis-decalin 391 instead.
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Nagilactones belong to the group of bioactive terpenoids, which was first isolated 
from the evergreen tree, Podocarpus nagi (Tunb.) Zoll. et Moritz in the late 1960s [223]. To 
date, a number of nagilactones, assigned from A to L, have been isolated from various 
Podocarpus species [16]. Among those, only nagilactone C (397), E (398), F (399), and G (400) 
are known to exhibit anticancer activities (Figure 20). 
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In the study conducted by Qi et al., nagilactone C (397) showed potent antiprolifera-
tive activity against cancer cell lines such as MDA-MB-231, AGS (gastric cancer), and Hela 
cell lines, with a GI50 value of 2–5 mM, whereas nagilactone F (399) and G (400) displayed 
even more potent activity than nagilactone C (397) against the same cancer cell lines (IC50 
≈ 1 mM) [224]. In another study, nagilactones were reported to possess cytotoxic effects 
against P-388 leukemia cells in vitro (GI50 of nagilactone G (400) ≈ 0.25 mM and nagilactone 
E (398) = 0.25 mg/mL) [225]. Moreover, in a recent study, nagilactone E (398) was found to 
dose-dependently reduce the growth of human NSCLC cells A549 and NIC-H1975, with 
a GI50 value of 5.2 and 3.6 μM, respectively [226]. Although there is still scarce information 
regarding efficacy of nagilactones in vivo, Guo et al. lately demonstrated in vivo efficacy 
of nagilactone E (398) in an A549 cell lung cancer xenograft mouse model [227]. The intra-
peritoneal injection of 10 mg/kg/d nagilactone E (398) suppressed tumor growth by 62% 
and inhibited tumor metastasis, without obvious toxicity. Furthermore, the authors have 
suggested RIOK2 as a potential target of nagilactone E (398) after carefully reviewing their 
Kaplan–Meier analysis and molecular docking study results [227]. RIOK2 is an atypical 
serine/threonine protein kinase related to the biogenesis of ribosome. Moreover, the ex-
pression level of RIOK2 is reported to be correlated with clinical outcome in NSCLC, in-
dicating its clinical significance [228]. However, low solubility of nagilactone E (398) might 
prevent it from further development despite the potent anticancer effects. Therefore, fu-
ture works should focus on structural modification to increase drug-like properties of 
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2.4.3. Anti-Cancer Activities of Nagilactones
Nagilactones belong to the group of bioactive terpenoids, which was first isolated
from the evergreen tree, Podocarpus nagi (Tunb.) Zoll. et Moritz in the late 1960s [223].
To date, a number of nagilactones, assigned from A to L, have been isolated from various
Podocarpus species [16]. Among those, only nagilactone C (397), E (398), F (399), and G (400)
are known to exhibit anticancer activities (Figure 20).
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In the study conducted by Qi et al., nagilactone C (397) showed potent antiproliferative
activity against cancer cell lines such as MDA-MB-231, AGS (gastric cancer), and Hela cell
lines, with a GI50 value of 2–5 mM, whereas nagilactone F (399) and G (400) displayed
even ore potent activity than nagilactone C (397) against the same cancer cell lines
(IC50 ≈ 1 mM) [224]. In another study, nagilactones were reported to possess cytotoxic
effects against P-388 leukemia cells in vitro (GI50 of nagilactone G (400) ≈ 0.25 mM and
nagilactone E (398) = 0.25 mg/mL) [225]. Moreover, in a recent study, nagilactone E
(398) was found to dose-dependently reduce the growth of human NSCLC cells A549
and NIC-H1975, with a GI50 value of 5.2 and 3.6 µM, respectively [226]. Although there
is still scarce information regarding efficacy of nagilactones in vivo, Guo et al. lately
demonstrated in vivo efficacy of nagilactone E (398) in an A549 cell lung cancer xenograft
mouse model [227]. The intraperitoneal injection of 10 mg/kg/d nagilactone E (398)
suppressed tumor growth by 62% and inhibited tumor metastasis, without obvious toxicity.
Furthermore, the authors have suggested RIOK2 as a potential target of nagilactone E
(398) after carefully reviewing their Kaplan–Meier analysis and molecular docking study
results [227]. RIOK2 is an atypical serine/threonine protein kinase related to the biogenesis
of ribosome. Moreover, the expression level of RIOK2 is reported to be correlated with
clinical outcome in NSCLC, indicating its clinical significance [228]. However, low solubility
of nagilactone E (398) might prevent it from further development despite the potent
anticancer effects. Therefore, future works should focus on structural modification to
increase drug-like properties of nagilactones and, more importantly, further validation of
possible protein targets of nagilactones.
2.4.4. Chemistry of Nagilactones
Synthesis of nagilactone F (399) has been extensively studied in comparison to other
nagilactones, being only one among nagilatone series with an available recent report.
The first total synthesis of Nagilactone F (399) was reported by Hayashi et al. [229]. The syn-
thetic approach by the group started with (+)-podocarpic acid, stereochemistry of which
was already established, and structure of all intermediates formed during the course of
reaction was fully characterized by the authors (Scheme 75). (+)-podocarpic acid methyl
ether (401) was converted to the enolide (402) over 9 steps, which was treated with potas-
sium t-butoxide in DMSO to give a diene-carboxylic acid (403). The authors presumed
the configuration of the 8:14-double bond in 403 to be in more thermodynamically stable
“E” form because 403 was produced under an equilibrium condition [229]. The diene-
carboxylic acid (403) was irradiated with medium pressure mercury lamp in 95% ethanol
to afford 8:9-enolide (404) as a single product. The enolide (404) underwent bromination
with NBS and subsequent debromination with Zn in DMF to afford dienolide ester 405,
which was then hydrolyzed with conc. H2SO4 to furnish a dienolide acid 406. The diene
acid 406 was treated with excess Pb(OAc)4 in benzene to produce a γ-lactone in 50% yield,
which was found out to be completely identical with natural nagilactone F (399) in IR and
1H-nmr comparisons [229].
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Fascinatingly, Hanessian et al. reported the asymmetric total synthesis of nagilactone 
F from a common precursor, which also provided access to CJ-14,445, LL-Z1271γ, and 
oidilolactones A, B, C, and D (structures not shown) [230]. In this review, we will focus on 
the synthesis of nagilactone F from the intermediate 19. The important synthetic strategies 
employed by the authors to obtain a tricyclic lactone key intermediate 19 include: (1) a 
Morita–Baylis–Hillman reaction, (2) a stereocontrolled bromolactonization reaction, and 
(3) a catalytic Reformatsky-type reaction. According to the retrosynthetic analysis pro-
vided by the group, the tricyclic lactone skeleton was sequentially prepared via construc-
tion of the AB podolactone ring, followed by the formation of D and C lactone ring (Figure 
21). 
Scheme 75. Total synthesis of nagilactone F by Hayashi et al. [229]. Reagents and conditions:
(i) t-BuOK, DMSO; (j) hν; (k) NBS, HCl3; (l) Zn, DMF; (m) H2SO4; (n) H2O; (O) Pb(OAc)4, hν.
Fascinatingly, Hanessian et al. reported the asymmetric total synthesis of nagilactone F
from a common precursor, which also provided access to CJ-14,445, LL-Z1271γ, and oidilo-
lactones A, B, C, and D (structures not shown) [230]. In this review, we will focus on the
synthesis of nagilactone F from the intermediate 19. The important synthetic strategies
employed by the authors to obtain a tricyclic lactone key intermediate 19 include: (1) a
Morita–Baylis–Hillman reaction, (2) a stereocontrolled bromolactonization reaction, and (3)
a catalytic Reformatsky-type reaction. According to the retrosynthetic analysis provided
by the group, the tricyclic lactone skeleton was sequentially prepared via construction of
the AB podolactone ring, followed by the formation of D and C lactone ring (Figure 21).
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able ieland- iescher ketone (407) following the ethods reported by Theodorakis and
Danishefsky groups [231,232], which led to the fully functionalized AB ring of podolactone
(408) over 9 steps (Scheme 76). Next, with the intermediate (408) in hand, construction of
the D lactone ring across C-4 and C-6 was attempted. To achieve this, 408 underwent a
Morita–Baylis–Hillman reaction, utilizing formaldehyde and dimethylphenylphosphine,
to give 410 in excellent yield. Based on the reaction sequence developed by Welch and
co-workers [233], obtained 410 was then subjected to bromolactonization, followed by
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elimination to give the corresponding tricyclic γ-lactone core 411, which was isolated as
the TES ether 412. During the introduction of the δ-lactone moiety, γ-lactone ring opening,
elimination, and poor yield occurred as major problems. This challenge was overcome
by the use of intramolecular Reformatsky reaction, which had seldom been utilized in
natural product synthesis [230]. The Reformatsky-type reaction between enone 412 and
ethyliodoacetate in the presence of NiCl2(PPh3)2 and Et3Zn furnished the desired tertiary
alcohol 409 as a single isomer.
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Toward the synthesis of nagilactone F, the common intermediate (409) was hydro-
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413, which was further treated with the Burgess reagent followed by HCl in THF to give 
lactol 414 (Scheme 77). Thus, the obtained lactol 414 was treated with isopropylmagne-
sium bromide following the protocol reported by Barrero and co-workers [234], which, as 
c e e 76. Sy t esis of t e co o tricyclic rec rsor 409 [230].
Toward the synthesis of nagilactone F, the common intermediate (409) was hydrolyzed
under acidic conditions and subsequently oxidized with DMP to provide aldehyde 413,
which was further treated with the Burgess reagent followed by HCl in THF to give lactol
414 (Scheme 77). Thus, the obtained lactol 414 was treated with isopropylmagnesium
bromide following the protocol reported by Barrero and co-workers [234], which, as op-
posed to expectations, led to low yield and moderate selectivity. Hence, the authors sought
to circumvent this problem. Gratifyingly, treatment of 414 with isopropenylmagnesium
bromide afforded dilactone 415 in good yield and high diasteroselectivity, which in turn
underwent homogeneous hydrogenation in the presence of Wilkinsons’s catalyst to furnish
nagilactone F (399).
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It selectively inhibits HSP90 function (IC50 = 160 
nM). 
[239] [29] 
RALs KF25706 (39) 
Significant growth-inhibitory activity against hu-
man breast carcinoma MX-1 cells transplanted into 
nude mice at a dose of 100 mg/kg twice daily for 
five consecutive iv injections. 
[240] [31] 
i [ ].
Significance of this ork is that it provided access to seven related norditerpenoid
dilactones, including nagilactone F (399), fro one co on precursor. e envision that
additional develop ent of such convergent and divergent synthetic approaches would be
necessary for the synthesis and derivatization of bioactive natural products.
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3. Summary
The biological activities of RALs, SLs, DAGLs, and DLs, including available patent in-
formation, are summarized in Table 1. Based on the research described above, the lactones
covered in this review have proved to be valuable compounds with promising bioactiv-
ities. For instance, L-783277 (4) exhibits a highly potent inhibitory activity against MEK
(IC50 = 4 nM), however, it displayed low kinome-wide selectivity. This selectivity issue was
overcome by rationally designed derivatives 99 and 100. 99 is a selective ALK1 inhibitor
(IC50 = 62 nM) and it is shown to effectively block BMP-9 induced ALK1 signaling in C2C12
cells. 100 is a dual VEGFR3 and VEGFR2 inhibitor (VEGFR3 IC50 = 1.15 nM, VEGFR2
IC50 = 3.56 nM) and its anti-lymphangiogenic and anti-angiogenic ability was demon-
strated both in 3D microfluidic tumor lymphangiogenesis assay and in vivo corneal assay.
Table 1. Biological activities of resorcylic acid lactones (RALs), sesquiterpene lactones (SLs), diacylglycerol lactones (DAGLs),
and diterpene lactones (DLs).
Class Compound Summary of Biological Activities Patents References
RALs Radicicol (1)
It selectively inhibits HSP90 function (IC50 = 20–23 nM).
Poor in vivo activity, probably due to chemical
instability in serum and its rapid conversion into
inactive metabolites.
[235–238] [24]
RALs 32 It selectively inhibits HSP90 function (IC50 = 160 nM). [239] [29]
RALs KF25706 (39)
Significant growth-inhibitory activity against human
breast carcinoma MX-1 cells transplanted into nude





It also inhibits the production of several cytokines such
as IL2, IL6, IFNγ, and TNFα.
It inhibited the growth of HT29 and HCT116 cells
in serum-free defined medium, IC50 = 0.078 mM
and 0.90 mM, respectively.
[241–243] [35]
RALs LL-Z1640-2 (3)
It selectively inhibits (TGF)-β-activated kinase 1
(TAK1) with high potency TAK1, (IC50 = 8.1 nM).
Strongly inhibition JNK/p38 pathway.
It also inhibits MEK1 (IC50 = 411 nM) and
three other MAPKKKs (IC50 ≥ 268 nM against MEKK1,
ASK1, and MEKK4).
It can be applied clinically to CNS autoimmune
disorders.
[244–246] [38]
RALs 74a-d Its activity is comparable to 3, but with improvedsolubility and pharmacokinetic properties. [46]
RALs ER803064 (79)
Increased metabolic stability and reduced potency than
3, active in vivo,
but the ED50 value (13.2 mg/kg, iv) was fairly high in
regard to TNF-α suppression
[246,247] [48]
RALs 83 and 84
A MEK1 and MEKK1 inhibitor.
Similar in vitro potency to natural product 3 and
improved in vivo potency by iv administration.
TNFα-PLAP IC50s: 32 nM for 83, 15 nM for 84.
ED50: 6.5 mg/kg for 84.
[247,248] [49]
RALs 90 Active against MNK2 kinase (IC50 = 7.2 µM). [50]
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Table 1. Cont.
Class Compound Summary of Biological Activities Patents References
RALs L-783277 (4)
Highly potent inhibitory activity against MEK
(IC50 of 4 nM).
Potent inhibitory activities against several kinases
including VEGFR2/3, FLT1/3/4, MEK1/2, KDR, and
PDGFRα but with low kinome selectivity.
[241,243,249,250] [47,52]
RALs 99
A selective and potent ALK1 inhibitor
It inhibits ALK1 with an IC50 value of 62 nM and
activates Smad4 by phosphorylating Smad1/5.
It acts by selectively blocking BMP9-induced ALK1
signaling in C2C12 cells.
[56–58]
RALs 100
Potent dual VEGFR3 and VEGFR2 inhibitor
(VEGFR3 IC50 = 1.15 nM, VEGFR2 IC50 = 3.56 nM).
It effectively suppresses both lymphangiogenesis and
angiogenesis in a 3D-microfluidic tumor
lymphangiogenesis assay and in vivo corneal assay.
[251] [54]
SLs Parthenolide (183)
IC50 values against SiHa and MCF-7 cells (8.42 and 9.54
µM, respectively). It prevents resistance of
MDA-MB-231 to doxorubicin and mitoxantrone.
Cytotoxicity in a wide variety of human cancers,
targeting IKK-β, and FAK 1 inhibition




It selectively eliminates AML stem cells.
DMAPT (190) significantly suppressed PC-3 tumor
growth until day 95 compared with control (P = 0.0007)
and resulted in greater tumor control than that
observed with docetaxel (P = 0.007).
In A549 subcutaneous xenograft, it reduced tumor
growth by 54% (100 mg/kg/day, po).
In UMUC-3 (transitional carcinoma) xenograft, it
suppressed tumor growth by 63%
(100 mg/kg oral twice/day).
It has an increased PK profile compared to 183
[252,254] [89,255,256]
SLs Alantolactone (184) IC50 values against MDA-MB 231 and HUVEC cells (40
µM and 14.2 µM, respectively). [257] [104]
SLs Deoxyelephantopin(185)
IC50 values against HCT116 (colorectal), K562 (CML),
KB (oral), and T47D (breast) cancer cell lines are 7.46,
4.02, 3.35, 1.86 µg/mL, respectively.
IC50 values against PC-3, CNE, and HL-60 cells are 4.6,
2.6, and 0.9 µM, respectively.
It is an inhibitor of NF-κB and targets PPAR-γ.
[258,259] [130,131,260,261]
SLs DETD-35 (232)
IC50 value against MDA-MB-231 is 3.5 µM.
In combination with paclitaxel,
it shows synergistic effects on MDA-MB 231 cells.
It also synergistic effects with vemurafenib to




It shows inhibitory activities on TR-LE cells.
IC50 value against SW-620 cells is 7.8 µM.
IC50 value against BGC-823 cells at 24 and 48 h is 32.80
and 23.12 µM, respectively.
[263] [162,163,264]
SLs 264 IC50 value against SW-620 cells is 3.3 µM. [163]
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Table 1. Cont.
Class Compound Summary of Biological Activities Patents References
SLs Antrocin (187)
IC50 value against MDA-MB-231 cells is 0.6 µM.
IC50 values against H441 (wt-EGFR) and H1975
(EGFRT790M) are 0.75 µM and 0.83 µM, respectively.
It suppressed tumorigenesis in lung cancer mouse
xenograft in vivo and enhanced tumor inhibitory
response in treatment with JAK2 inhibitor.
It showed no apparent systematic toxicity in a 28-day
rat study (at 37.5 mg/kg).
[246,265–267] [171–173]
SLs EM23 (188) IC50 values against Caski and SiHa cell lines are 5.8and 6.6 µM, respectively. [179]
SLs Brevilin A (189)
It selectively inhibits growth of DU145
and MDA-MB-468.
It inhibits JAK-STAT signaling pathway by attenuating
JAKs activity and blocking STAT3 signaling
(IC50 = 10.6 µM) in cancer cells.
[268] [186]
DAGLs AJH-836 (315) It is a selective ligand for PKCε.(Ki of PKCα = 46 nM, Ki of PKCε = 1.43 nM)
[14,199]
DLs Andrographolide(373)
IC50 value against PCa cells is 19.95 µM.
IC50 value against A549 cells of PTX + 30 µM 373 is






IC50 = 6.3 µM and 1.6 µM for MKN-45 and AGS cell
lines, respectively. [208]
DLs SRJ23(375) 50-fold improved IC50 for PCa cells (0.4 µM) than 373. [211]
DLs Nagilactone C (397) IC50 = 2–5 mM against MDA-MB-231, AGS, and Helacell lines. [224]
DLs Nagilactone E (398)
IC50 = 5.2 and 3.6 µM against A549 and NIC-H1975,
respectively.
In an A549 xenograft mouse model
(10 mg/kg/d, ip), it suppressed tumor growth by 62%
and inhibited tumor metastasis without apparent
toxicity
[226,227]
Among sesquiterpene lactones reviewed in this work, parthenolide (183) inhibited
growth of SiHa and MCF-7 cells with an IC50 value of 8.42 and 9.54 µM, respectively.
Furthermore, parthenolide (183), in combination with docetaxel, enhanced survival, and
reduced metastases in a mouse xenograft model of breast cancer without any observed
apparent toxicity [80]. In addition, Parthenolide (183), as a main component of feverfew,
underwent a phase 1 clinical trial to assess its pharmacokinetics and toxicity [81,270]. Pre-
existing poor solubility and bioavailability issues of parthenolide (183) led to development
of DMAPT (190). Methods for preparation of parthenolide (183) derivatives are patented
by Fusan R., et al. and Crooks, P., et al. [252,253]. DMAPT (190) has an increased PK profile
compared to parthenolide (183) and significantly suppressed tumor growth in subcuta-
neous xenografts of A549 and UMUC-3 (transitional carcinoma cells) in athymic nude mice
by 54% (100 mg/kg/day, oral) and 63% (100 mg/kg twice/day, oral), respectively. DMAPT
(190) is reported to be in a phase 1 clinical trial in hematological malignancies in the United
Kingdom [89,271,272]. DETD-35 (232), a derivative of deoxyelephantopin (185), inhibits
growth of MDA-MB-231 cells with an IC50 value of 3.5 µM. Notably, it shows synergistic
effects with vemurafenib to overcome BRAFV600E mutant melanoma in a mouse xenograft
model. Antrocin (187) inhibits growth of EGFR-harboring cell lines H441 (wt-EGFR) and
H1975 (EGFRT790M) with an IC50 value of 0.75 and 0.83 µM, respectively. It suppressed
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tumorigenesis in lung cancer mouse xenograft in vivo. Moreover, it showed no apparent
systematic in a 28-day rat study (at 37.5 mg/kg).
Among diterpene lactones, andrographolide (373) inhibited growth of PCa cells with
an IC50 value of 19.95 µM and enhanced 5-FU induced apoptosis in 5-FU resistant cancer
cells (HCT116/5-FUR). Use of andrographolide (373) derivatives in the manufacture of
medicaments and structural modification of the natural product to increase biological
activities are patented [205,269]. Andrographolide (373) is reported to be in a phase 2
clinical trial as treatment in colorectal neoplasms [273]. Nagilactone E (398) suppressed
tumor growth by 62% in an A549 xenograft mouse model (10 mg/kg/day) and inhibited
tumor metastasis without apparent toxicity.
Overall, it may be said that these natural and synthetic lactones of various classes,
given the activities described in this review, possess suitable properties to initiate further
preclinical and clinical studies leading to advancement into new drugs.
4. Conclusions and Future Prospects
The pharmacologically significant natural products have been providing inspiration
and guidance to make a paradigm shift for innovative drug development strategies, which
serve as a great starting point for initiation of drug discovery programs. Taking into account
the researches elucidated above, the natural and synthetic lactones addressed in this review
strongly suggest that they are promising therapeutic leads for oncology drug discovery
program. Moreover, the synthetic studies of above-mentioned natural products and their
useful analogs will open up a whole new research field, contributing to the foundation of
intriguing new realm in the design and synthesis of natural products and their analogs as
well.
In this review, we mainly focused on recognized natural and synthetic analogs of lac-
tones in each classification (RALs, SLs, DAGLs, and DLs) with notable antitumor activities
and we described their recent advancements made in the field of drug discovery. However,
to reach a clinically viable drug from a potent natural product/-derived compound, there
are still several remaining challenges to be overcome: (a) difficulties in sophisticated syn-
thetic modification due to structural complexity, (b) relatively poor drug-like properties and
target specificity, and (c) elusive exact biological targets and mechanism of action. In this
light, our extensive study on structural modification of L-783277 (4) demonstrated that sim-
ple changes in chemical structure such as saturation or rigidification bring about significant
improvements in terms of potency, target-selectivity, and pharmacokinetic property. In ad-
dition, the research mentioned above exemplified identification of possible cellular targets
of DET (185) by using synthetic DET-related probes. We believe that ongoing studies on the
synthesis and biological evaluation of such compounds result in the establishment of novel
methods for innovative drug design strategies and target identification. Furthermore, we
anticipate that these findings would provide biologists as well as chemists with valuable
insights and resources to achieve the ultimate goal towards cancer drug discovery program.
5. Materials and Methods
A comprehensive search was accomplished by using the following databases to obtain
the recent and relevant references in regards to natural and synthetic lactones: PubMed,
Science-Direct, Springer, ACS, NIH, Google Scholar, MEDLINE, EBSCO, Web of Science,
ClinicalTrials.gov, and Sci-Finder from 1946 to 2020. The keywords used include ‘natural lac-
tones’, ‘synthetic lactones’, ‘macrocyclic lactones’, ‘resorcylic acid lactones’, ‘sesquiterpene
lactones’, ‘diacylglycerol lactones’, and ‘diterpene lactones’ alone or combined with the
keywords ‘derivatives’, ‘anticancer’, ‘signaling pathway’, ‘apoptosis’, ‘cell cycle’, ‘necrosis’,
‘mutation’, ‘angiogenesis’, ‘metastasis’, ‘kinase inhibition’, ‘PI3K’, ‘MAPK’, ‘ROS’, ‘target
identification’, and ‘drug discovery’.
Exclusively, references in English were included in this review due to language barrier.
Compound entries and references were selected according to the following criteria: avail-
ability of researches focused on (a) anticancer activities, (b) total synthesis, (c) synthetic
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derivatives, (d) in-vitro and in-vivo studies, and (e) clinical studies. On the other side,
compound entries and references were ruled out according to the following criteria: (a)
researches, which are not focused on anticancer activity, (b) researches without sufficient
information on synthesis, and (c) researches without sufficient information on biological
evaluation. In addition, only 4 resorcylic acid lactones have been selected as representative
because biology and chemistry of resorcylic acid lactones are generally well summarized
in previous reviews [12,21].
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Bouwmeester, H. Biosynthesis and localization of parthenolide in glandular trichomes of feverfew (Tanacetum parthenium L.
Schulz Bip.). Phytochemistry 2011, 72, 1739–1750. [CrossRef] [PubMed]
168. Matsuda, H.; Kageura, T.; Inoue, Y.; Morikawa, T.; Yoshikawa, M. Absolute stereostructures and syntheses of saussureamines A,
B, C, D and E, amino acid–sesquiterpene conjugates with gastroprotective effect, from the roots of Saussurea lappa. Tetrahedron
2000, 56, 7763–7777. [CrossRef]
169. Geethangili, M.; Tzeng, Y.-M. Review of pharmacological effects of Antrodia camphorata and its bioactive compounds. Evid.
Based Complementaryy Altern. Med. 2011, 2011, 212641.
170. Ao, Z.-H.; Xu, Z.-H.; Lu, Z.-M.; Xu, H.-Y.; Zhang, X.-M.; Dou, W.-F. Niuchangchih (Antrodia camphorata) and its potential in
treating liver diseases. J. Ethnopharmacol. 2009, 121, 194–212. [CrossRef]
171. Rao, Y.K.; Wu, A.T.; Geethangili, M.; Huang, M.-T.; Chao, W.-J.; Wu, C.-H.; Deng, W.-P.; Yeh, C.-T.; Tzeng, Y.-M. Identification
of antrocin from Antrodia camphorata as a selective and novel class of small molecule inhibitor of Akt/mTOR signaling in
metastatic breast cancer MDA-MB-231 cells. Chem. Res. Toxicol. 2011, 24, 238–245. [CrossRef]
172. Yeh, C.-T.; Huang, W.-C.; Rao, Y.K.; Ye, M.; Lee, W.-H.; Wang, L.-S.; Tzeng, D.T.; Wu, C.-H.; Shieh, Y.-S.; Huang, C.-Y.F. A
sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2/STAT3 signaling via microRNA let-7c and
induces apoptosis in lung cancer cells. Carcinogenesis 2013, 34, 2918–2928. [CrossRef]
173. Chen, J.-H.; Wu, A.T.; Tzeng, D.T.; Huang, C.-C.; Tzeng, Y.-M.; Chao, T.-Y. Antrocin, a bioactive component from Antrodia cin-
namomea, suppresses breast carcinogenesis and stemness via downregulation of β-catenin/Notch1/Akt signaling. Phytomedicine
2019, 52, 70–78. [CrossRef]
174. Chen, Y.-A.; Tzeng, D.T.; Huang, Y.-P.; Lin, C.-J.; Lo, U.; Wu, C.-L.; Lin, H.; Hsieh, J.-T.; Tang, C.-H.; Lai, C.-H. Antrocin
sensitizes prostate cancer cells to radiotherapy through inhibiting PI3K/AKT and MAPK signaling pathways. Cancers 2019, 11,
34. [CrossRef]
175. Li, F.-Z.; Li, S.; Zhang, P.-P.; Huang, Z.-H.; Zhang, W.-B.; Gong, J.; Yang, Z. A chiral pool approach for asymmetric syntheses of
(−)-antrocin,(+)-asperolide C, and (−)-trans-ozic acid. Chem. Comm. 2016, 52, 12426–12429. [CrossRef]
176. Angamuthu, V.; Tai, D.-F. Synthesis of Natural (−)-Antrocin and Its Enantiomer via Stereoselective Aldol Reaction. Molecules
2020, 25, 831. [CrossRef] [PubMed]
177. Diaz, S.; Cuesta, J.; González, A.; Bonjoch, J. Synthesis of (−)-nakamurol A and assignment of absolute configuration of
diterpenoid (+)-Nakamurol A. J. Org. Chem. 2003, 68, 7400–7406. [CrossRef] [PubMed]
178. Skepper, C.K.; Quach, T.; Molinski, T.F. Total synthesis of enigmazole A from Cinachyrella enigmatica. Bidirectional bond
constructions with an ambident 2, 4-disubstituted oxazole synthon. J. Am. Chem. Soc. 2010, 132, 10286–10292. [CrossRef]
[PubMed]
179. Shao, F.-Y.; Wang, S.; Li, H.-Y.; Chen, W.-B.; Wang, G.-C.; Ma, D.-L.; Wong, N.S.; Xiao, H.; Liu, Q.-Y.; Zhou, G.-X. EM23, a natural
sesquiterpene lactone, targets thioredoxin reductase to activate JNK and cell death pathways in human cervical cancer cells.
Oncotarget 2016, 7, 6790. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 1052 64 of 67
180. Tonissen, K.F.; Di Trapani, G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol. Nutr. Food Res.
2009, 53, 87–103. [CrossRef]
181. Lincoln, D.T.; Ali, E.E.; Tonissen, K.F.; Clarke, F.M. The thioredoxin-thioredoxin reductase system: Over-expression in human
cancer. Anticancer Res. 2003, 23, 2425.
182. Powis, G.; Mustacich, D.; Coon, A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic. Biol. Med. 2000,
29, 312–322. [CrossRef]
183. Chan, C.-O.; Jin, D.-P.; Dong, N.-P.; Chen, S.-B.; Mok, D.K.W. Qualitative and quantitative analysis of chemical constituents of
Centipeda minima by HPLC-QTOF-MS & HPLC-DAD. J. Pharm. Biomed. Anal. 2016, 125, 400–407.
184. ChangLong, L.; HeZhen, W.; YongPing, H.; YanFang, Y.; YanWen, L.; JianWen, L. 6-O-Angeloylenolin induces apoptosis through
a mitochondrial/caspase and NF-κB pathway in human leukemia HL60 cells. Biomed. Pharmacother. 2008, 62, 401–409. [CrossRef]
185. Li, C.; Wu, H.; Yang, Y.; Liu, J.; Chen, Z. Sesquiterpene lactone 6-O-angeloylplenolin reverses vincristine resistance by inhibiting
YB-1 nuclear translocation in colon carcinoma cells. Oncol. Lett. 2018, 15, 9673–9680. [CrossRef]
186. Chen, X.; Du, Y.; Nan, J.; Zhang, X.; Qin, X.; Wang, Y.; Hou, J.; Wang, Q.; Yang, J. Brevilin A, a novel natural product, inhibits
janus kinase activity and blocks STAT3 signaling in cancer cells. PLoS ONE 2013, 8, e63697. [CrossRef]
187. Lee, M.M.-L.; Chan, B.D.; Wong, W.-Y.; Leung, T.-W.; Qu, Z.; Huang, J.; Zhu, L.; Lee, C.-S.; Chen, S.; Tai, W.C.-S. Synthesis and
Evaluation of Novel Anticancer Compounds Derived from the Natural Product Brevilin A. ACS Omega 2020, 5, 14586–14596.
[CrossRef] [PubMed]
188. Cooke, M.; Zhou, X.; Casado-Medrano, V.; Lopez-Haber, C.; Baker, M.J.; Garg, R.; Ann, J.; Lee, J.; Blumberg, P.M.; Kazanietz, M.G.
Characterization of AJH-836, a diacylglycerol-lactone with selectivity for novel PKC isozymes. J. Biol. Chem. 2018, 293, 8330–8341.
[CrossRef]
189. Kang, J.-H.; Kim, S.Y.; Lee, J.; Marquez, V.E.; Lewin, N.E.; Pearce, L.V.; Blumberg, P.M. Macrocyclic diacylglycerol-bis-lactones as
conformationally constrained analogues of diacylglycerol-lactones. Interactions with protein kinase C. J. Med. Chem. 2004, 47,
4000–4007. [CrossRef] [PubMed]
190. Garg, R.; Benedetti, L.G.; Abera, M.B.; Wang, H.; Abba, M.; Kazanietz, M.G. Protein kinase C and cancer: What we know and
what we do not. Oncogene 2014, 33, 5225–5237. [CrossRef] [PubMed]
191. Mochly-Rosen, D.; Das, K.; Grimes, K.V. Protein kinase C, an elusive therapeutic target? Nat. Rev. Drug Discov. 2012, 11, 937–957.
[CrossRef]
192. Bosco, R.; Melloni, E.; Celeghini, C.; Rimondi, E.; Vaccarezza, M.; Zauli, G. Fine tuning of protein kinase C (PKC) isoforms in
cancer: Shortening the distance from the laboratory to the bedside. Mini-Rev. Med. Chem. 2011, 11, 185–199. [CrossRef]
193. Lee, J.; Lewin, N.E.; Acs, P.; Blumberg, P.M.; Marquez, V.E. Conformationally Constrained Analogues of Diacylglycerol.
13.1 Protein Kinase C Ligands Based on Templates Derived from 2, 3-Dideoxy-l-erythro (threo)-hexono-1, 4-lactone and 2-
Deoxyapiolactone. J. Med. Chem. 1997, 40, 1560. [CrossRef]
194. Ono, Y.; Fujii, T.; Igarashi, K.; Kuno, T.; Tanaka, C.; Kikkawa, U.; Nishizuka, Y. Phorbol ester binding to protein kinase C requires
a cysteine-rich zinc-finger-like sequence. Proc. Natl. Acad. Sci. USA 1989, 86, 4868–4871. [CrossRef]
195. Kang, J.-H.; Kim, Y.; Won, S.-H.; Park, S.-K.; Lee, C.W.; Kim, H.-M.; Lewin, N.E.; Perry, N.A.; Pearce, L.V.; Lundberg, D.J. Polar
3-alkylidene-5-pivaloyloxymethyl-5′-hydroxymethyl-γ-lactones as protein kinase C ligands and antitumor agents. Bioorg. Med.
Chem. Lett. 2010, 20, 1008–1012. [CrossRef]
196. Duan, D.; Sigano, D.M.; Kelley, J.A.; Lai, C.C.; Lewin, N.E.; Kedei, N.; Peach, M.L.; Lee, J.; Abeyweera, T.P.; Rotenberg, S.A.
Conformationally constrained analogues of diacylglycerol. 29. Cells sort diacylglycerol-lactone chemical zip codes to produce
diverse and selective biological activities. J. Med. Chem. 2008, 51, 5198–5220. [CrossRef] [PubMed]
197. Nishizuka, Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 1995, 9, 484–496. [CrossRef] [PubMed]
198. Ann, J.; Yoon, S.; Baek, J.; Kim, D.H.; Lewin, N.E.; Hill, C.S.; Blumberg, P.M.; Lee, J. Design and synthesis of protein kinase C
epsilon selective diacylglycerol lactones (DAG-lactones). Eur. J. Med. Chem. 2015, 90, 332–341. [CrossRef] [PubMed]
199. Cooke, M.; Casado-Medrano, V.; Ann, J.; Lee, J.; Blumberg, P.M.; Abba, M.C.; Kazanietz, M.G. Differential Regulation of Gene
Expression in Lung Cancer Cells by Diacyglycerol-Lactones and a Phorbol Ester Via Selective Activation of Protein Kinase C
Isozymes. Sci. Rep. 2019, 9, 1–15. [CrossRef]
200. Boden, E.P.; Keck, G.E. Proton-transfer steps in Steglich esterification: A very practical new method for macrolactonization. J. Org.
Chem. 1985, 50, 2394–2395. [CrossRef]
201. Seigler, D. Plant Secondary Metabolites; Springer: Berlin/Heidelberg, Germany, 1998.
202. Farhat, F.; Tariq, A.; Zikrea, A.; Fatima, R.N. Diterpenes from Different Fungal Sources and Their 13C-NMR Data. In Terpenes and
Terpenoids; IntechOpen: London, UK, 2018; p. 111.
203. Thisoda, P.; Rangkadilok, N.; Pholphana, N.; Worasuttayangkurn, L.; Ruchirawat, S.; Satayavivad, J. Inhibitory effect of
Andrographis paniculata extract and its active diterpenoids on platelet aggregation. Eur. J. Pharmacol. 2006, 553, 39–45. [CrossRef]
204. Chakravarti, R.; Chakravarti, M.D. Andrographolide, the Active Constituent of Andrographis Paniculata Nees. A Preliminary
Communication. Ind. Med. Gaz. 1951, 86, 96.
205. Aromdee, C. Modifications of andrographolide to increase some biological activities: A patent review (2006–2011). Expert Opin.
Ther. Pat. 2012, 22, 169–180. [CrossRef]
206. Mishra, S.K.; Tripathi, S.; Shukla, A.; Oh, S.H.; Kim, H.M. Andrographolide and analogues in cancer prevention. Front. Biosci.
Elite Ed. 2015, 7, 255. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 1052 65 of 67
207. Dai, L.; Wang, G.; Pan, W. Andrographolide inhibits proliferation and metastasis of SGC7901 gastric cancer cells. Biomed Res. Int.
2017, 2017. [CrossRef]
208. Monger, A.; Boonmuen, N.; Suksen, K.; Saeeng, R.; Kasemsuk, T.; Piyachaturawat, P.; Saengsawang, W.; Chairoungdua, A.
Inhibition of topoisomerase IIα and induction of apoptosis in gastric cancer cells by 19-triisopropyl andrographolide. Asian Pac. J.
Cancer Rev. 2017, 18, 2845.
209. Mir, H.; Kapur, N.; Singh, R.; Sonpavde, G.; Lillard, J.W., Jr.; Singh, S. Andrographolide inhibits prostate cancer by targeting cell
cycle regulators, CXCR3 and CXCR7 chemokine receptors. Cell Cycle 2016, 15, 819–826. [CrossRef] [PubMed]
210. Chun, J.Y.; Tummala, R.; Nadiminty, N.; Lou, W.; Liu, C.; Yang, J.; Evans, C.P.; Zhou, Q.; Gao, A.C. Andrographolide, an herbal
medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth. Genes Cance 2010, 1, 868–876. [CrossRef]
[PubMed]
211. Wong, H.C.; Wong, C.C.; Sagineedu, S.R.; Loke, S.C.; Lajis, N.H.; Stanslas, J. SRJ23, a new semisynthetic andrographolide
derivative: In vitro growth inhibition and mechanisms of cell cycle arrest and apoptosis in prostate cancer cells. Cell Biol. Toxicol.
2014, 30, 269–288. [CrossRef]
212. Wang, W.; Guo, W.; Li, L.; Fu, Z.; Liu, W.; Gao, J.; Shu, Y.; Xu, Q.; Sun, Y.; Gu, Y. Andrographolide reversed 5-FU resistance in
human colorectal cancer by elevating BAX expression. Biochem. Pharmacol. 2016, 121, 8–17. [CrossRef]
213. Lin, H.-H.; Shi, M.-D.; Tseng, H.-C.; Chen, J.-H. Andrographolide sensitizes the cytotoxicity of human colorectal carcinoma cells
toward cisplatin via enhancing apoptosis pathways in vitro and in vivo. Toxicol. Sci. 2014, 139, 108–120. [CrossRef]
214. Shu, Y.; Sun, J.; Cai, P.; Wang, W.; Han, X.; Gu, Y. An open-label, randomized, controlled clinical trial to explore the curative effects
between the treatment of capecitabine and andrographolide and the single capecitabine in the patients with pathological and/or
histologic diagnosed unresectable, advanced, recurrent, and metastatic colorectal cancer. Am. J. Clin. Oncol. 2017, 35, TPS819.
215. Mi, S.; Xiang, G.; Yuwen, D.; Gao, J.; Guo, W.; Wu, X.; Wu, X.; Sun, Y.; Su, Y.; Shen, Y. Inhibition of autophagy by andrographolide
resensitizes cisplatin-resistant non-small cell lung carcinoma cells via activation of the Akt/mTOR pathway. Toxicol. Appl. Pharm.
2016, 310, 78–86. [CrossRef]
216. Yuan, H.; Sun, B.; Gao, F.; Lan, M. Synergistic anticancer effects of andrographolide and paclitaxel against A549 NSCLC cells.
Pharm. Biol. 2016, 54, 2629–2635. [CrossRef]
217. Lim, J.C.W.; Jeyaraj, E.J.; Sagineedu, S.R.; Wong, W.S.F.; Stanslas, J. SRS06, a new semisynthetic andrographolide derivative with
improved anticancer potency and selectivity, inhibits nuclear factor-κB nuclear binding in the A549 non-small cell lung cancer
cell line. Pharmacology 2015, 95, 70–77. [CrossRef]
218. Gao, H.-T.; Wang, B.-L.; Li, W.-D.Z. Synthetic applications of homoiodo allylsilane II. Total syntheses of (−)-andrographolide and
(+)-rostratone. Tetrahedron 2014, 70, 9436–9448. [CrossRef]
219. Li, W.-D.Z.; Yang, J.-H. A novel synthesis of functionalized allylsilanes. Organic Lett. 2004, 6, 1849–1852. [CrossRef] [PubMed]
220. Fujita, T.; Fujitani, R.; Takeda, Y.; Takaishi, Y.; Yamada, T.; Kido, M.; Miura, I. On the diterpenoids of Andrographis paniculata:
X-ray crystallographic analysis of andrographolide and structure determination of new minor diterpenoids. Chem. Pharm. Bull.
1984, 32, 2117–2125. [CrossRef]
221. Yang, L.; Wurm, T.; Sharma Poudel, B.; Krische, M.J. Enantioselective Total Synthesis of Andrographolide and 14-Hydroxy-
Colladonin: Carbonyl Reductive Coupling and trans-Decalin Formation by Hydrogen Transfer. Angew. Chem. 2020, 59,
23169–23173. [CrossRef] [PubMed]
222. Iwasaki, K.; Wan, K.K.; Oppedisano, A.; Crossley, S.W.; Shenvi, R.A. Simple, chemoselective hydrogenation with thermodynamic
stereocontrol. J. Am. Chem. Soc. 2014, 136, 1300–1303. [CrossRef]
223. Hayashi, Y.; Takahashi, S.; Ona, H.; Sakan, T. Structures of nagilactone a, b, c, and d, novel nor-and bisnorditerpenoids. Tetrahedron
Lett. 1968, 9, 2071–2076. [CrossRef]
224. Qi, Y.Y.; Su, J.; Zhang, Z.J.; Li, L.W.; Fan, M.; Zhu, Y.; Wu, X.D.; Zhao, Q.S. Two New Anti-Proliferative C18-Norditerpenes from
the Roots of Podocarpus macrophyllus. Chem. Biodiversity 2018, 15, e1800043. [CrossRef]
225. Sato, K.; Inaba, Y.; Park, H.-S.; Akiyama, T.; Koyama, T.; Fukaya, H.; Aoyagi, Y.; Takeya, K. Cytotoxic Bisnor-and Norditerpene
Dilactones Having 7α, 8α-Epoxy-9, 11-enolide Substructure from Podocarpus macrophyllus D. D ON. Chem. Pharm. Bull. 2009,
57, 668–679. [CrossRef]
226. Zhang, L.-L.; Feng, Z.-L.; Su, M.-X.; Jiang, X.-M.; Chen, X.; Wang, Y.; Li, A.; Lin, L.-G.; Lu, J.-J. Downregulation of Cyclin B1
mediates nagilactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells. Eur. J. Pharmacol. 2018, 830, 17–25.
[CrossRef]
227. Guo, J.; Jiang, X.-M.; Chen, X.-P.; Wang, Y.-T.; Li, A.; Lin, L.-G.; Li, H.; Lu, J.-J. Identification of nagilactone E as a protein synthesis
inhibitor with anticancer activity. Acta Pharmacol. Sin. 2020, 41, 698–705.
228. Liu, K.; Chen, H.-L.; Wang, S.; Gu, M.-M.; Chen, X.-M.; Zhang, S.-L.; Yu, K.-J.; You, Q.-S. High expression of RIOK2 and NOB1
predict human non-small cell lung cancer outcomes. Sci. Rep. 2016, 6, 28666. [CrossRef] [PubMed]
229. Hayashi, Y.; Matsumoto, T.; Nishizawa, M.; Togami, M.; Hyono, T.; Nishikawa, N.; Uemura, M.; Sakan, T. Total synthesis of
nagilactone F, a biologically active norditerpenoid dilactone isolated from Podocarpus nagi. J. Org. Chem. 1982, 47, 3428–3433.
[CrossRef]
230. Hanessian, S.; Boyer, N.; Reddy, G.J.; Deschênes-Simard, B. Total synthesis of oidiodendrolides and related norditerpene dilactones
from a common precursor: Metabolites CJ-14,445, LL-Z1271γ, oidiolactones A, B, C, and D, and nagilactone F. Org. Lett. 2009, 11,
4640–4643. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2021, 22, 1052 66 of 67
231. Ling, T.; Chowdhury, C.; Kramer, B.A.; Vong, B.G.; Palladino, M.A.; Theodorakis, E.A. Enantioselective synthesis of the
antiinflammatory agent (−)-acanthoic acid. J. Org. Chem. 2001, 66, 8843–8853. [CrossRef] [PubMed]
232. Waters, S.P.; Tian, Y.; Li, Y.-M.; Danishefsky, S.J. Total synthesis of (−)-scabronine G, an inducer of neurotrophic factor production.
J. Am. Chem. Soc. 2005, 127, 13514–13515. [CrossRef]
233. Welch, S.; Hagan, C.; White, D.; Fleming, W.; Trotter, J. A stereoselective total synthesis of the antifungal mold metabolite 7.alpha.-
methoxy-3a,10b-dimethyl-1,2,3,3a.alpha.,5a.alpha.,7,10b.beta.,10c.alpha.-octahydro-4H,9H-furo[2′,3′,4′:4,5]naphtho[2,1-
c]pyran-4,10-dione. J. Am. Chem. Soc. 1977, 99, 549–556. [CrossRef]
234. Barrero, A.F.; Sánchez, J.F.; Elmerabet, J.; Jiménez-González, D.; Macías, F.A.; Simonet, A.M. Enantiospecific syntheses of the
potent bioactives nagilactone F and the mould metabolite LL-Z1271α an evaluation of their allelopathic potential. Tetrahedron
1999, 55, 7289–7304. [CrossRef]
235. Feng, L.; Hwang, D. Method of Use of Radicicol for Treatment of Inflammation and Endotoxemia. International Patent Application
WO9625928A1, 29 August 1996.
236. Winssinger, N.; Barluenga, S.; Karplus, M. Synthesis of Resorcylic Acid Lactones Useful as Therapeutic Agents. International
Patent Application WO2009091921A1, 23 July 2009.
237. Chen, R.; Rubenstein, A.E.; Shen, X.; Yu, J.-C.; Giovannini, M. Preparation of Radicicol and Related Macrocyclic Compounds Which
Inhibit HSP90 for Therapeutic Use in the Treatment of Neurofibromatosis. International Patent Application WO2008150302A1, 11
December 2008.
238. Der, S.S. Reagents, Compositions Based on Heat Shock Response Activation and/or Antioxidant Response, and Methods for
Improving Viability and Function of Cells, Tissues and Organs. International Patent Application WO2017214709A1, 21 December
2017.
239. Danishefsky, S.J.; Garbaccio, R.M.; Baeschlin, D.K.; Stachel, S.J.; Solit, D.; Shtil, A.; Rosen, N. Preparation of therapeutic macrocyclic
natural product derivatives. International Patent Application WO2002016369A2, 28 February 2002.
240. Botchkareva, N.; Ahluwalia, G.S.; Shander, D. Use of Heat Shock Protein Inhibitors for the Reduction of Hair Growth. International
Patent Application WO2005105023A1, 10 November 2005.
241. Santi, D.V.; Reid, R.C.; Hutchinson, R.C.; Sundermann, K.F.; Lau, J. Resorcylic Acid Lactone Kinase Inhibitors, and Their
Therapeutic Use for the Treatment of Cancers and Other Conditions. International Patent Application WO2006036941A2, 6 April
2006.
242. Tremble, P. Methods and Compositions Comprising an Ubiquitin Activator for Inhibiting Narrowing in Mammalian Vascular
Pathways. U.S. Patent Application US20040243224A1, 2 December 2004.
243. Winssinger, N.; Barluenga, S. Preparation of Macrolides as Irreversible Inhibitors Useful for the Treatment of Kinase-Related
Pathologies. International Patent Application WO2011036299A1, 31 March 2011.
244. Alici, E.; Duru, A.; Sutlu, T. Enhanced Gene Delivery to Natural Killer Cells, Hematopoietic Stem Cells and Macrophages.
International Patent Application WO2017059177A2, 6 April 2017.
245. Pollack, A.; Dvashi, Z. Treatments for Fibrotic Diseases Using Transforming Growth Factor β Activated Kinase 1 (TAK1) inhibitors.
U.S. Patent Application US20160206591A1, 21 July 2016.
246. Pearce, C.; Croatt, M.P.; Fakhouri, L.; Oberlies, N.H. Preparation of Difluororesorcylic acid Lactone Derivatives for Use as TAK-1
Inhibitors. International Patent Application WO2016196256A2, 8 December 2016.
247. Boivin, R.; Chiba, K.; Davis, H.A.; Diepitro, L.; Du, H.; Eguchi, Y.; Fujita, M.; Gilbert, S.; Goto, M.; Harmange, J.C. Preparation of
Macrocyclic Compounds for Use in Pharmaceutical and Cosmetic Compositions Which Regulate Various Genes Involved in
Immune and Inflammatory Responses. International Patent Application WO2003076424A1, 18 September 2003.
248. Chiba, K.; Du, H.; Eguchi, Y.; Fujita, M.; Goto, M.; Gusovsky, F.; Harmange, J.-C.; Inoue, A.; Kawada, M.; Kawai, T. Prepa-
ration of Macrocyclic Compounds for the Treatment of Inflammation and Autoimmune Disorders. U.S. Patent Application
US20040224936A1, 11 November 2004.
249. Neel, B.G.; Mohi, G. Combination of mTOR Inhibitor and a Tyrosine Kinase Inhibitor for the Treatment of Neoplasms. International
Patent Application WO2004004644A2, 15 January 2004.
250. Litvin, O.; Rosen, N.; Pe’er, D. Methods of Treating Cancer Using Combinations of Interferon and MAPK Pathway Inhibitors. U.S.
Patent Application US20150086509A120150326, 26 March 2015.
251. Sim, T.; Yoon, H.; Kim, J. Preparation of Resorcyclic Acid Lactone Compound as Anticancer Agent. Korea Patent Application
KR1387400B1, 21 April 2014.
252. Fusan, R.; Jordan, C.T.; Kolev, J.N. Parthenolide Derivatives, Methods for Their Preparation and Their Use as Anticancer Agents.
U.S. Patent Application US20160115508A1, 28 April 2016.
253. Al-Fatlawi, A.A.; Al-Fatlawi, A.A.; Rahisuddin, I.; Ahmad, A. Effect of parthenolide on growth and apoptosis regulatory genes of
human cancer cell lines. Pharm. Biol. 2015, 53, 104–109. [CrossRef]
254. Crooks, P.; Jordan, C.T.; Wei, X. Use of Parthenolide Derivatives as Antileukemic and Cytotoxic Agents. U.S. Patent Application
US008716329B2, 5 June 2014.
255. Shanmugam, R.; Kusumanchi, P.; Cheng, L.; Crooks, P.; Neelakantan, S.; Matthews, W.; Nakshatri, H.; Sweeney, C.J. A water-
soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFκB and generating reactive oxygen
species. Prostate 2010, 70, 1074–1086. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 1052 67 of 67
256. Pei, S.; Guzman, M.L.; Nasim, S.; Shi, L.; Crooks, P.A.; Jordan, C.T. Analysis of the Anti-Leukemia Mechanism of Parthenolide;
American Society of Hematology: Washington, DC, USA, 2009.
257. Kim, Y.; Chun, J.; Kim, M. Pharmaceutical Composition for Preventing and Treating Breast Cancer Containing Inula Helenium
Hexane Fraction Having STAT3 Inhibitory Activity or Compound Isolated Therefrom as Active Ingredient. International Patent
Application WO2015130081, 9 March 2015.
258. Shyur, L.; Chao, W.; Cheng, Y. Use of Deoxyelephantopin (DET) and Analogues Thereof for Reducing Side Effects of an
Anti-cancer Agent. U.S. Patent Application US9173868B2, 3 November 2015.
259. Shyur, L.; Chao, W.; Cheng, Y. Use of Deoxyelephantopin (DET) and Analogues Thereof for Treatment of Melanoma. U.S. Patent
Application US8754121B2, 17 June 2014.
260. Kabeer, F.A.; Rajalekshmi, D.S.; Nair, M.S.; Prathapan, R. Molecular mechanisms of anticancer activity of deoxyelephantopin in
cancer cells. Integr. Med. Res. 2017, 6, 190–206. [CrossRef]
261. Su, M.; Wu, X.; Chung, H.Y.; Li, Y.; Ye, W. Antiproliferative activities of five Chinese medicinal herbs and active compounds in
Elephantopus scaber. Nat. Prod. Commun. 2009, 4, 1934578X0900400802. [CrossRef]
262. Shyur, L.; Lee, K.; Nakagawa, K.; Feng, J.; Chen, J.; Lee, W.; Cheng, Y.; Huang, J. Sesquiterpene Derivatives and Their Use in
Inflammation or Cancer Treatment. U.S. Patent Application US10238631B2, 26 April 2019.
263. Su, W.; Jia, H.; Zhang, W.; Yan, X.; Duan, J.; Wang, T.; Cai, Y. Costunolide Derivatives. U.S. Patent Application US7488836B2, 10
February 2009.
264. Yan, Z.; Xu, T.; An, Z.; Hu, Y.; Chen, W.; Ma, J.; Shao, C.; Zhu, F. Costunolide induces mitochondria-mediated apoptosis in human
gastric adenocarcinoma BGC-823 cells. BMC Complement. Altern. Med. 2019, 19, 1–10. [CrossRef] [PubMed]
265. Sheu, C.; Hattori, M. Compounds Isolated from Antrodia Cinnamomea and Use Thereof. U.S. Patent Application
US20100210865A1, 19 August 2010.
266. Yang, Z.; Tzeng, Y.; Li, C.; Luo, T.; Shi, H.; Yeh, C. Method for Chemical Synthesis of Antrocin and Use Thereof for Suppressing
Non-Small Cell Lung Cancer. U.S. Patent Application US9045450B2, 2 June 2015.
267. Tzeng, Y.; Yang, Z.; Yeh, C. Antrocin Containing Pharmaceutical Compositions for Inhibiting Cancer Cells. U.S. Patent Application
US20120100175A1, 26 April 2012.
268. Zhao, C.; Chen, X.; Du, Y.; Yang, J.; Wang, Q. Application of Brevilin A When Serving as JAK-STATs Signal Target Inhibitor.
CN102836151, 26 December 2012.
269. Wang, Y.; Jiang, X.; Jiang, J.; Zhang, Z.; Yang, Z.; Yu, P. Andrographolide Derivatives and Use Thereof in Manufacture of
Medicaments. International Patent Application WO2009018780A1, 12 February 2009.
270. Murphy, J.; Heptinstall, S.; Mitchell, J. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention.
Lancet 1988, 332, 189–192. [CrossRef]
271. Hewamana, S.; Lin, T.T.; Jenkins, C.; Burnett, A.K.; Jordan, C.T.; Fegan, C.; Brennan, P.; Rowntree, C.; Pepper, C. The novel nuclear
factor-κB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy
with fludarabine. Clin. Cancer Res. 2008, 14, 8102–8111. [CrossRef] [PubMed]
272. Peese, K. New agents for the treatment of leukemia: Discovery of DMAPT (LC-1). Drug Discov. Today 2010, 7, 322. [CrossRef]
273. Yanhong, G. Study of Andrographolides with or Without Capecitabine to Treat Colorectal Cancer. NCT01993472. Available
online: https://clinicaltrials.gov/ct2/show/NCT01993472 (accessed on 29 November 2020).
